66 results on '"Oka, S"'
Search Results
2. In vivo sequence variability of human immunodeficiency virus type 1 envelope gp120: association of V2 extension with slow disease progression
- Author
-
Shioda, T, primary, Oka, S, additional, Xin, X, additional, Liu, H, additional, Harukuni, R, additional, Kurotani, A, additional, Fukushima, M, additional, Hasan, M K, additional, Shiino, T, additional, Takebe, Y, additional, Iwamoto, A, additional, and Nagai, Y, additional
- Published
- 1997
- Full Text
- View/download PDF
3. In vivo induction of apoptosis in the thymus by administration of mycobacterial cord factor (trehalose 6,6'-dimycolate)
- Author
-
Ozeki, Y, primary, Kaneda, K, additional, Fujiwara, N, additional, Morimoto, M, additional, Oka, S, additional, and Yano, I, additional
- Published
- 1997
- Full Text
- View/download PDF
4. (1-->3) beta-D-glucan as a quantitative serological marker for Pneumocystis carinii pneumonia
- Author
-
Yasuoka, A, primary, Tachikawa, N, additional, Shimada, K, additional, Kimura, S, additional, and Oka, S, additional
- Published
- 1996
- Full Text
- View/download PDF
5. Immune complex transfer enzyme immunoassay that is more sensitive and specific than western blotting for detection of antibody immunoglobulin G to human immunodeficiency virus type 1 in serum with recombinant pol and gag proteins as antigens
- Author
-
Hashida, S, primary, Hashinaka, K, additional, Nishikata, I, additional, Oka, S, additional, Shimada, K, additional, Saito, A, additional, Takamizawa, A, additional, Shinagawa, H, additional, Yano, S, additional, and Kojima, H, additional
- Published
- 1995
- Full Text
- View/download PDF
6. A novel synthetic lipid A analog with low endotoxicity, DT-5461, prevents lethal endotoxemia
- Author
-
Sato, K, primary, Yoo, Y C, additional, Fukushima, A, additional, Saiki, I, additional, Takahashi, T A, additional, Fujihara, M, additional, Tono-Oka, S, additional, and Azuma, I, additional
- Published
- 1995
- Full Text
- View/download PDF
7. Successful treatment of Pneumocystis carinii Pneumonia in mice with benanomicin A (ME1451)
- Author
-
Yasuoka, A, primary, Oka, S, additional, Komuro, K, additional, Shimizu, H, additional, Kitada, K, additional, Nakamura, Y, additional, Shibahara, S, additional, Takeuchi, T, additional, Kondo, S, additional, and Shimada, K, additional
- Published
- 1995
- Full Text
- View/download PDF
8. Measurement of human immunodeficiency virus type 1 p24 in serum by an ultrasensitive enzyme immunoassay, the two-site immune complex transfer enzyme immunoassay
- Author
-
Hashida, S, primary, Hashinaka, K, additional, Nishikata, I, additional, Oka, S, additional, Shimada, K, additional, Saitoh, A, additional, Takamizawa, A, additional, Shinagawa, H, additional, and Ishikawa, E, additional
- Published
- 1995
- Full Text
- View/download PDF
9. A naturally occurring single basic amino acid substitution in the V3 region of the human immunodeficiency virus type 1 env protein alters the cellular host range and antigenic structure of the virus
- Author
-
Shioda, T, primary, Oka, S, additional, Ida, S, additional, Nokihara, K, additional, Toriyoshi, H, additional, Mori, S, additional, Takebe, Y, additional, Kimura, S, additional, Shimada, K, additional, and Nagai, Y, additional
- Published
- 1994
- Full Text
- View/download PDF
10. Major antigenic region on the integrase (IN) protein of human immunodeficiency virus type 1 determined by reactivity of human sera and a monoclonal antibody to IN protein
- Author
-
Tachibana, Y, primary, Yasuda, A, additional, Kurata, T, additional, Oka, S, additional, Shimada, K, additional, and Kojima, A, additional
- Published
- 1994
- Full Text
- View/download PDF
11. Detection of anti-human immunodeficiency virus type 1 (HIV-1) immunoglobulin G in urine by an ultrasensitive enzyme immunoassay (immune complex transfer enzyme immunoassay) with recombinant reverse transcriptase as an antigen
- Author
-
Hashinaka, K, primary, Hashida, S, additional, Hirota, K, additional, Saitoh, A, additional, Nakata, A, additional, Shinagawa, H, additional, Oka, S, additional, Shimada, K, additional, and Ishikawa, E, additional
- Published
- 1994
- Full Text
- View/download PDF
12. Evaluation of acridinium-ester-labeled DNA probes for identification of Mycobacterium tuberculosis and Mycobacterium avium-Mycobacterium intracellulare complex in culture
- Author
-
Goto, M, primary, Oka, S, additional, Okuzumi, K, additional, Kimura, S, additional, and Shimada, K, additional
- Published
- 1991
- Full Text
- View/download PDF
13. Detection of Pneumocystis carinii sequences by polymerase chain reaction: animal models and clinical application to noninvasive specimens
- Author
-
Kitada, K, primary, Oka, S, additional, Kimura, S, additional, Shimada, K, additional, Serikawa, T, additional, Yamada, J, additional, Tsunoo, H, additional, Egawa, K, additional, and Nakamura, Y, additional
- Published
- 1991
- Full Text
- View/download PDF
14. Rapid identification of serotypes of Mycobacterium avium-M. intracellulare complex by using infected swine sera and reference antigenic glycolipids
- Author
-
Ikawa, H, primary, Oka, S, additional, Murakami, H, additional, Hayashi, A, additional, and Yano, I, additional
- Published
- 1989
- Full Text
- View/download PDF
15. Epitope-dependent effect of long-term cART on maintenance and recovery of HIV-1-specific CD8 + T cells.
- Author
-
Kuse N, Gatanaga H, Zhang Y, Chikata T, Oka S, and Takiguchi M
- Subjects
- Humans, Anti-HIV Agents pharmacology, Anti-HIV Agents therapeutic use, CD8-Positive T-Lymphocytes cytology, CD8-Positive T-Lymphocytes drug effects, CD8-Positive T-Lymphocytes immunology, Epitopes, T-Lymphocyte drug effects, Epitopes, T-Lymphocyte immunology, HIV Infections drug therapy, HIV Infections immunology, HIV Infections therapy, HIV-1 drug effects, HIV-1 immunology, Antiretroviral Therapy, Highly Active
- Abstract
Importance: HIV-1-specific CD8
+ T cells are anticipated to become effector cells for curative treatment using the "shock and kill" approach in people living with HIV-1 (PLWH) under combined antiretroviral therapy (cART). Previous studies demonstrated that the frequency of HIV-1-specific CD8+ T cells is reduced under cART and their functional ability remains impaired. These studies analyzed T-cell responses to a small number of HIV-1 epitopes or overlapping HIV-1 peptides. Therefore, the features of CD8+ T cells specific for HIV-1 epitopes under cART remain only partially clarified. Here, we analyzed CD8+ T cells specific for 63 well-characterized epitopes in 90 PLWH. We demonstrated that CD8+ T cells specific for large numbers of HIV-1 epitopes were maintained in an epitope-dependent fashion under long-term cART and that long-term cART enhanced or restored the ability of HIV-1-specific T cells to proliferate in vitro . This study implies that some HIV-1-specific T cells would be useful as effector cells for curative treatment., Competing Interests: The authors declare no conflict of interest.- Published
- 2023
- Full Text
- View/download PDF
16. Immunological Control of HIV-1 Disease Progression by Rare Protective HLA Allele.
- Author
-
Zhang Y, Chikata T, Kuse N, Murakoshi H, Gatanaga H, Oka S, and Takiguchi M
- Subjects
- Humans, Alleles, CD8-Positive T-Lymphocytes, Virus Replication, HLA-B Antigens genetics, Epitopes, Disease Progression, Epitopes, T-Lymphocyte genetics, HIV-1 genetics, HIV Infections, HIV Seropositivity genetics
- Abstract
Rare HLA alleles such as HLA-B57 are associated with slow progression to AIDS. However, the evidence for the advantage of rare protective alleles is limited, and the mechanism is still unclear. Although the prevalence of HLA-B*67:01 is only 1.2% in Japan, HLA-B*67:01-positive (HLA-B*67:01
+ ) individuals had the lowest plasma viral load (pVL) and highest CD4 count in HIV-1 clade B-infected Japanese individuals. We investigated the mechanism of immunological control of HIV-1 by a rare protective allele, HLA-B*67:01. We identified six novel HLA-B*67:01-restricted epitopes and found that T cells specific for four epitopes were significantly associated with good clinical outcomes, pVL and/or CD4 count. The wild type or cross-reactive sequences of three protective and immunodominant Pol and Gag epitopes were found in around 95% of the circulating HIV-1, indicating that T cells specific for three conserved or cross-reactive epitopes contributed to good clinical outcomes. One escape mutation (Nef71K) in the Nef protective epitope, which was selected by T cells restricted by either HLA allele in the HLA-B*67:01-C*07:02 haplotype, affected the HLA-B*67:01-restricted RY11-specific T-cell recognition. These results imply that the further accumulation of the Nef71K mutation in the population will negatively affect the control of HIV-1 replication by RY11-specific CD8+ T cells in HIV-1-infected HLA-B*67:01+ individuals. The present study demonstrated that conserved or cross-reactive epitope-specific T cells mainly contribute to control of HIV-1 by a rare protective allele, HLA-B*67:01. IMPORTANCE HLA-B57 is a relatively rare allele around world and the strongest protective HLA allele in Caucasians and African black individuals infected with HIV-1. Previous studies suggested that the advantage of this allele in HIV-1 disease progression is due to a strong functional ability of HLA-B57-restricted Gag-specific T cells and lower fitness of mutant viruses selected by the T cells. HLA-B*57 is a very rare allele and has not been reported as a protective allele in Asian countries, whereas a rare allele, HLA-B*67:01, was shown to be a protective allele in Japan. Therefore, the analysis of HLA-B*67:01-restricted T cells is important to clarify the mechanism of immunological control of HIV-1 by a rare protective HLA allele in Asia. We found that HLA-B*67:01-restricted T cells specific for three conserved or cross-reactive Gag and Pol epitopes are associated with good clinical outcomes in HLA-B*67:01+ individuals. It is expected that T cells specific for conserved or cross-reactive epitopes contribute to a curing treatment.- Published
- 2022
- Full Text
- View/download PDF
17. Control of HIV-1 Replication by CD8 + T Cells Specific for Two Novel Pol Protective Epitopes in HIV-1 Subtype A/E Infection.
- Author
-
Nguyen HT, Kuse N, Zhang Y, Murakoshi H, Maeda Y, Tamura Y, Maruyama R, Tran GV, Nguyen TV, Nguyen KV, Oka S, Chikata T, and Takiguchi M
- Subjects
- HLA-B Antigens immunology, Humans, T-Lymphocytes, Cytotoxic immunology, pol Gene Products, Human Immunodeficiency Virus immunology, CD8-Positive T-Lymphocytes immunology, Epitopes, T-Lymphocyte immunology, HIV Infections immunology, HIV-1 physiology, Virus Replication
- Abstract
Although many HIV-1-specific CD8
+ T cell epitopes have been identified and used in various HIV-1 studies, most of these epitopes were derived from HIV-1 subtypes B and C. Only 17 well-defined epitopes, none of which were protective, have been identified for subtype A/E infection. The roles of HIV-1-specific T cells have been rarely analyzed for subtype A/E infection. In this study, we identified six novel HLA-B*15:02-restricted optimal HIV-1 subtype A/E epitopes and then analyzed the presentation of these epitopes by HIV-1 subtype A/E virus-infected cells and the T cell responses to these epitopes in treatment-naive HIV-1 subtype A/E-infected HLA-B*15:02+ Vietnamese individuals. Responders to the PolTY9 or PolLF10 epitope had a significantly lower plasma viral load (pVL) than nonresponders among HLA-B*15:02+ individuals, whereas no significant difference in pVL was found between responders to four other epitopes and nonresponders. The breadth of T cell responses to these two Pol epitopes correlated inversely with pVL. These findings suggest that HLA-B*15:02-restricted T cells specific for PolTY9 and PolLF10 contribute to the suppression of HIV-1 replication in HLA-B*15:02+ individuals. The HLA-B*15:02-associated mutation Pol266I reduced the recognition of PolTY9-specific T cells in vitro but did not affect HIV-1 replication by PolTY9-specific T cells in Pol266I mutant virus-infected individuals. These findings indicate that PolTY9-specific T cells suppress replication of the Pol266I mutant virus even though the T cells selected this mutant. This study demonstrates the effective role of T cells specific for these Pol epitopes to control circulating viruses in HIV-1 subtype A/E infection. IMPORTANCE It is expected that HIV-1-specific CD8+ T cells that effectively suppress HIV-1 replication will contribute to HIV-1 vaccine development and therapy to achieve an HIV cure. T cells specific for protective epitopes were identified in HIV-1 subtype B and C infections but not in subtype A/E infection, which is epidemic in Southeast Asia. In the present study, we identified six T cell epitopes derived from the subtype A/E virus and demonstrated that T cells specific for two Pol epitopes effectively suppressed HIV-1 replication in treatment-naive Vietnamese individuals infected with HIV-1 subtype A/E. One of these Pol protective epitopes was conserved among circulating viruses, and one escape mutation was accumulated in the other epitope. This mutation did not critically affect HIV-1 control by specific T cells in HIV-1 subtype A/E-infected individuals. This study identified two protective Pol epitopes and characterized them in cases of HIV-1 subtype A/E infection.- Published
- 2022
- Full Text
- View/download PDF
18. Impact of Micropolymorphism Outside the Peptide Binding Groove in the Clinically Relevant Allele HLA-C*14 on T Cell Responses in HIV-1 Infection.
- Author
-
Chikata T, Paes W, Kuse N, Partridge T, Gatanaga H, Zhang Y, Kuroki K, Maenaka K, Ternette N, Oka S, Borrow P, and Takiguchi M
- Subjects
- Alleles, Epitopes, T-Lymphocyte, HIV-1, Humans, Peptides metabolism, CD8-Positive T-Lymphocytes immunology, HIV Infections immunology, HIV Seropositivity, HLA-C Antigens genetics
- Abstract
There is increasing evidence for the importance of human leukocyte antigen C (HLA-C)-restricted CD8
+ T cells in HIV-1 control, but these responses are relatively poorly investigated. The number of HLA-C-restricted HIV-1 epitopes identified is much smaller than those of HLA-A-restricted or HLA-B-restricted ones. Here, we utilized a mass spectrometry-based approach to identify HIV-1 peptides presented by HLA-C*14:03 protective and HLA-C*14:02 nonprotective alleles. We identified 25 8- to 11-mer HLA-I-bound HIV-1 peptides from HIV-1-infected HLA-C*14:02+ /14:03+ cells. Analysis of T cell responses to these peptides identified novel 6 T cell epitopes targeted in HIV-1-infected HLA-C*14:02+ /14:03+ subjects. Analyses using HLA stabilization assays demonstrated that all 6 epitope peptides exhibited higher binding to and greater cell surface stabilization of HLA-C*14:02 than HLA-C*14:03. T cell response magnitudes were typically higher in HLA-C*14:02+ than HLA-C*14:03+ individuals, with responses to the Pol KM9 and Nef epitopes being significantly higher. The results show that HLA-C*14:02 can elicit stronger T cell responses to HIV-1 than HLA-C*14:03 and suggest that the single amino acid difference between these HLA-C14 subtypes at position 21, outside the peptide-binding groove, indirectly influences the stability of peptide-HLA-C*14 complexes and induction/expansion of HIV-specific T cells. Taken together with a previous finding that KIR2DL2+ NK cells recognized HLA-C*14:03+ HIV-1-infected cells more than HLA-C*14:02+ ones, the present study indicates that these HLA-C*14 subtypes differentially impact HIV-1 control by T cells and NK cells. IMPORTANCE Some human leukocyte antigen (HLA) class I alleles are associated with good clinical outcomes in HIV-1 infection and are called protective HLA alleles. Identification of T cell epitopes restricted by protective HLA alleles can give important insight into virus-immune system interactions and inform design of immune-based prophylactic/therapeutic strategies. Although epitopes restricted by many protective HLA-A/B alleles have been identified, protective HLA-C alleles are relatively understudied. Here, we identified 6 novel T cell epitopes presented by both HLA-C*14:02 (no association with protection) and HLA-C*14:03 (protective) using a mass spectrometry-based immunopeptidome profiling approach. We found that these peptides bound to and stabilized HLA-C*14:02 better than HLA-C*14:03 and observed differences in induction/expansion of epitope-specific T cell responses in HIV-infected HLA-C*14:02+ versus HLA-C*14:03+ individuals. These results enhance understanding of how the microstructural difference at position 21 between these HLA-C*14 subtypes may influence cellular immune responses involved in viral control in HIV-1 infection.- Published
- 2022
- Full Text
- View/download PDF
19. Collaboration of a Detrimental HLA-B*35:01 Allele with HLA-A*24:02 in Coevolution of HIV-1 with T Cells Leading to Poorer Clinical Outcomes.
- Author
-
Kuse N, Murakoshi H, Akahoshi T, Chikata T, James KL, Gatanaga H, Rowland-Jones SL, Oka S, and Takiguchi M
- Subjects
- CD8-Positive T-Lymphocytes, Cross-Sectional Studies, Epitopes, T-Lymphocyte genetics, HIV Infections virology, HLA-A24 Antigen genetics, HLA-B Antigens chemistry, HLA-B Antigens genetics, HLA-B35 Antigen genetics, Humans, Mutation, Viral Load, Alleles, HIV-1 genetics, HLA-A24 Antigen chemistry, HLA-A24 Antigen metabolism, HLA-B35 Antigen chemistry, HLA-B35 Antigen metabolism
- Abstract
Although mutant-specific T cells are elicited in some individuals infected with HIV-1 mutant viruses, the detailed characteristics of these T cells remain unknown. A recent study showed that the accumulation of strains expressing Nef135F, which were selected by HLA-A*24:02-restricted T cells, was associated with poor outcomes in individuals with the detrimental HLA-B*35:01 allele and that HLA-B*35:01-restricted NefYF9 (Nef135-143)-specific T cells failed to recognize target cells infected with Nef135F mutant viruses. Here, we investigated HLA-B*35:01-restricted T cells specific for the NefFF9 epitope incorporating the Nef135F mutation. Longitudinal T-cell receptor (TCR) clonotype analysis demonstrated that 3 types of HLA-B*35:01-restricted T cells (wild-type [WT] specific, mutant specific, and cross-reactive) with different T cell repertoires were elicited during the clinical course. HLA-B*35:01
+ individuals possessing wild-type-specific T cells had a significantly lower plasma viral load (pVL) than those with mutant-specific and/or cross-reactive T cells, even though the latter T cells effectively recognized the mutant virus-infected cells. These results suggest that mutant-specific and cross-reactive T cells could only partially suppress HIV-1 replication in vivo . An e x vivo analysis of the T cells showed higher expression of PD-1 on cross-reactive T cells and lower expression of CD160/2B4 on the mutant-specific T cells than other T cells, implying that these inhibitory and stimulatory molecules are key to the reduced function of these T cells. In the present study, we demonstrate that mutant-specific and cross-reactive T cells do not contribute to the suppression of HIV-1 replication in HIV-1-infected individuals, even though they have the capacity to recognize mutant virus-infected cells. Thus, the collaboration of HLA-A*24:02 with the detrimental allele HLA-B*35:01 resulted in the coevolution of HIV-1 alongside virus-specific T cells, leading to poorer clinical outcomes. IMPORTANCE HIV-1 escape mutations are selected under pressure from HIV-1-specific CD8+ T cells. Accumulation of these mutations in circulating viruses impairs the control of HIV-1 by HIV-1-specific T cells. Although it is known that HIV-1-specific T cells recognizing mutant virus were elicited in some individuals infected with a mutant virus, the role of these T cells remains unclear. Accumulation of phenylalanine at HIV-1 Nef135 (Nef135F), which is selected by HLA-A*24:02-restricted T cells, led to poor clinical outcome in individuals carrying the detrimental HLA-B*35:01 allele. In the present study, we found that HLA-B*35:01-restricted mutant-specific and cross-reactive T cells were elicited in HLA-B*35:01+ individuals infected with the Nef135F mutant virus. These T cells could not effectively suppress HIV-1 replication in vivo even though they could recognize mutant virus-infected cells in vitro . Mutant-specific and cross-reactive T cells expressed lower levels of stimulatory molecules and higher levels of inhibitory molecules, respectively, suggesting a potential mechanism whereby these T cells fail to suppress HIV-1 replication in HIV-1-infected individuals.- Published
- 2021
- Full Text
- View/download PDF
20. Effect of Difference in Consensus Sequence between HIV-1 Subtype A/E and Subtype B Viruses on Elicitation of Gag-Specific CD8 + T Cells and Accumulation of HLA-Associated Escape Mutations.
- Author
-
Zhang Y, Murakoshi H, Chikata T, Akahoshi T, Tran GV, Nguyen TV, Gatanaga H, Nguyen KV, Oka S, Kuse N, and Takiguchi M
- Subjects
- Asian People, Consensus Sequence, Epitopes, T-Lymphocyte genetics, Epitopes, T-Lymphocyte immunology, HIV Infections virology, HIV-1 immunology, HLA-B Antigens genetics, HLA-B Antigens immunology, HLA-C Antigens genetics, HLA-C Antigens immunology, Humans, Mutation, T-Lymphocytes, Cytotoxic immunology, Virus Replication, CD8-Positive T-Lymphocytes immunology, Genes, gag genetics, HIV Infections immunology, HIV-1 genetics, Immune Evasion genetics
- Abstract
The Gag280 mutation is associated with HLA-C*01:02 but not with HLA-B*52:01 in subtype A/E-infected individuals, whereas this mutation is associated with HLA-B*52:01 but not with HLA-C*01:02 in subtype B infections. Although it is known that the Gag280 mutant is selected by HLA-B*52:01-restricted GagRI8 (Gag275-282)-specific T cells in subtype B infections, it remains unknown why this Gag280 mutation is associated with HLA-C*01:02 rather than HLA-B*52:01 in subtype A/E infections. The subtype B and A/E viruses have different consensus sequence, with Thr and Val at Gag280, respectively. To clarify the effect of this difference in Gag280 consensus sequence, we investigated the role of HLA-C*01:02-restricted GagYI9 (Gag277-285)-specific T cells in selection of Gag280 mutations in subtype A/E-infected Vietnamese and subtype B-infected Japanese individuals. GagYI9-4V-specific T cells, which were frequently elicited in Vietnamese individuals infected with the consensus-type A/E virus, failed to recognize GagV280T mutant A/E virus-infected cells. GagYI9-4T mutant epitope-specific T cells, which were weakly elicited in individuals infected with the mutant A/E virus, had weak or no ability to recognize the mutant virus. These results account for the mechanism for selection and accumulation of GagV280T mutants in the case of subtype A/E infections. In contrast, HLA-C*01:02-restricted GagYI9-4T-specific T cells were weakly elicited in Japanese individuals infected with the subtype B virus, explaining why HLA-C*01:02-restricted Gag280 mutations are not accumulated in the case of a subtype B infection. The present study demonstrated that a difference in the Gag280 consensus sequence influenced the elicitation of the GagYI9-specific T cells involved in the accumulation of HLA-C*01:02-associated Gag280 mutations. IMPORTANCE HIV-1 mutations escaped from HIV-specific CD8
+ T cells are mostly detected as HLA-associated mutations. A diversity of HLA-associated mutations is somewhat distinct to each race and region, since HLA allele distribution differs among them. A difference in the consensus sequence among HIV-1 subtypes may also influence the diversity of HLA-associated mutations. HLA-C*01:02-associated GagV280T and HLA-B*52:01-associated GagT280A/S mutations were previously identified in HIV-1 subtype A/E-infected and subtype B-infected individuals, respectively, though these subtype viruses have a different consensus sequence at Gag280. We demonstrated that the GagV280T mutant virus was selected by HLA-C*01:02-restricted GagYI9-4V-specific T cells in subtype A/E-infected Vietnamese but that HLA-C*01:02-restricted GagYI9-4T-specific T cells were weakly elicited in subtype B-infected Japanese. Together with our recent study which demonstrated the mechanism for the accumulation of HLA-B*52:01-associated mutations, we clarified the mechanism for the accumulation of different Gag280 mutations and the effect of the difference in the consensus sequence on the accumulation of escape mutations., (Copyright © 2021 Zhang et al.)- Published
- 2021
- Full Text
- View/download PDF
21. Utility of the Rapid Antigen Detection Test E. histolytica Quik Chek for the Diagnosis of Entamoeba histolytica Infection in Nonendemic Situations.
- Author
-
Yanagawa Y, Shimogawara R, Endo T, Fukushima R, Gatanaga H, Hayasaka K, Kikuchi Y, Kobayashi T, Koga M, Koibuchi T, Miyagawa T, Nagata A, Nakata H, Oka S, Otsuka R, Sakai K, Shibuya M, Shingyochi H, Tsuchihashi E, Watanabe K, and Yagita K
- Subjects
- Antigens, Protozoan, Cross-Sectional Studies, Enzyme-Linked Immunosorbent Assay, Feces, Humans, Japan, Sensitivity and Specificity, Entamoeba histolytica genetics, Entamoebiasis diagnosis
- Abstract
Entamoeba histolytica infection is an increasingly common sexually transmitted infection in Japan. Currently, stool ova and parasite examination (O&P) is the only approved diagnostic method. Here, we assessed the utility of the commercially available rapid antigen detection test (Quik Chek) for E. histolytica A multicenter cross-sectional study was conducted. Stool samples that had been submitted for O&P were included. The samples were subjected to both Quik Chek and PCR, and the Quik Chek results were assessed in comparison with PCR as the reference standard. E. histolytica infection was confirmed in 5.8% (38/657) of the samples and comprised 20 diarrheal and 18 nondiarrheal cases. The overall sensitivity and specificity of Quik Chek were 44.7% (95% confidence interval, 30.1 to 60.3) and 99.8% (99.1 to 100), respectively. The sensitivity of Quik Chek was higher for diarrheal cases (60.0%) than for nondiarrheal cases (27.8%). Furthermore, the combined use of Quik Chek with O&P increased the sensitivity (78.9%), especially for diarrheal cases (up to 90%). The E. histolytica burden assessed by quantitative PCR was similar between Quik Chek-positive and -negative samples. The Quik Chek assay sensitivity was lower for cyst-containing stools than for trophozoite-containing stools, although it was shown that cultured E. histolytica clinical strains from Quik Chek-negative cyst-containing stools exhibited antigenicity in vitro The present study confirmed the high specificity of Quik Chek for E. histolytica infection. Combined use with O&P increased the sensitivity of detection, facilitating the use of Quik Chek in point-of-care settings in nonendemic situations., (Copyright © 2020 Yanagawa et al.)
- Published
- 2020
- Full Text
- View/download PDF
22. Role of Escape Mutant-Specific T Cells in Suppression of HIV-1 Replication and Coevolution with HIV-1.
- Author
-
Zhang Y, Kuse N, Akahoshi T, Chikata T, Gatanaga H, Oka S, Murakoshi H, and Takiguchi M
- Subjects
- CD8-Positive T-Lymphocytes, Cell Line, Epitopes, T-Lymphocyte genetics, HIV Infections virology, HLA-B Antigens genetics, Humans, Mutation, HIV-1 genetics, HIV-1 immunology, T-Lymphocytes immunology, Virus Replication physiology
- Abstract
The accumulation of HIV-1 escape mutations affects HIV-1 control by HIV-1-specific T cells. Some of these mutations can elicit escape mutant-specific T cells, but it still remains unclear whether they can suppress the replication of HIV-1 mutants. It is known that HLA-B*52:01-restricted RI8 (Gag 275 to 282; RMYSPTSI) is a protective T cell epitope in HIV-1 subtype B-infected Japanese individuals, though 3 Gag280A/S/V mutations are found in 26% of them. Gag280S and Gag280A were HLA-B*52:01-associated mutations, whereas Gag280V was not, implying a different mechanism for the accumulation of Gag280 mutations. In this study, we investigated the coevolution of HIV-1 with RI8-specific T cells and suppression of HIV-1 replication by its escape mutant-specific T cells both in vitro and in vivo HLA-B*52:01
+ individuals infected with Gag280A/S mutant viruses failed to elicit these mutant epitope-specific T cells, whereas those with the Gag280V mutant one effectively elicited RI8-6V mutant-specific T cells. These RI8-6V-specific T cells suppressed the replication of Gag280V virus and selected wild-type virus, suggesting a mechanism affording no accumulation of the Gag280V mutation in the HLA-B*52:01+ individuals. The responders to wild-type (RI8-6T) and RI8-6V mutant peptides had significantly higher CD4 counts than nonresponders, indicating that the existence of not only RI8-6T-specific T cells but also RI8-6V-specific ones was associated with a good clinical outcome. The present study clarified the role of escape mutant-specific T cells in HIV-1 evolution and in the control of HIV-1. IMPORTANCE Escape mutant-specific CD8+ T cells were elicited in some individuals infected with escape mutants, but it is still unknown whether these CD8+ T cells can suppress HIV-1 replication. We clarified that Gag280V mutation were selected by HLA-B*52:01-restricted CD8+ T cells specific for the GagRI8 protective epitope, whereas the Gag280V virus could frequently elicit GagRI8-6V mutant-specific CD8+ T cells. GagRI8-6V mutant-specific T cells had a strong ability to suppress the replication of the Gag280V mutant virus both in vitro and in vivo In addition, these T cells contributed to the selection of wild-type virus in HLA-B*52:01+ Japanese individuals. We for the first time demonstrated that escape mutant-specific CD8+ T cells can suppress HIV-1 replication and play an important role in the coevolution with HIV-1. Thus, the present study highlighted an important role of escape mutant-specific T cells in the control of HIV-1 and coevolution with HIV-1., (Copyright © 2020 Zhang et al.)- Published
- 2020
- Full Text
- View/download PDF
23. Identification of Immunodominant HIV-1 Epitopes Presented by HLA-C*12:02, a Protective Allele, Using an Immunopeptidomics Approach.
- Author
-
Chikata T, Paes W, Akahoshi T, Partridge T, Murakoshi H, Gatanaga H, Ternette N, Oka S, Borrow P, and Takiguchi M
- Subjects
- Animals, Antigen Presentation, CD8-Positive T-Lymphocytes immunology, Chromatography, Liquid, Epitopes, T-Lymphocyte immunology, Epitopes, T-Lymphocyte isolation & purification, HIV Infections virology, HIV-1 chemistry, Humans, Immunodominant Epitopes isolation & purification, Mice, Tandem Mass Spectrometry, HIV Infections immunology, HIV-1 immunology, HLA-C Antigens metabolism, Immunodominant Epitopes immunology, Proteomics methods
- Abstract
Despite the fact that the cell surface expression level of HLA-C on both uninfected and HIV-infected cells is lower than those of HLA-A and -B, increasing evidence suggests an important role for HLA-C and HLA-C-restricted CD8
+ T cell responses in determining the efficiency of viral control in HIV-1-infected individuals. Nonetheless, HLA-C-restricted T cell responses are much less well studied than HLA-A/B-restricted ones, and relatively few optimal HIV-1 CD8+ T cell epitopes restricted by HLA-C alleles have been defined. Recent improvements in the sensitivity of mass spectrometry (MS)-based approaches for profiling the immunopeptidome present an opportunity for epitope discovery on a large scale. Here, we employed an MS-based immunopeptidomic strategy to characterize HIV-1 peptides presented by a protective allele, HLA-C*12:02. We identified a total of 10,799 unique 8- to 12-mer peptides, including 15 HIV-1 peptides. The latter included 2 previously reported immunodominant HIV-1 epitopes, and analysis of T cell responses to the other HIV-1 peptides detected revealed an additional immunodominant epitope. These findings illustrate the utility of MS-based approaches for epitope definition and emphasize the capacity of HLA-C to present immunodominant T cell epitopes in HIV-infected individuals, indicating the importance of further evaluation of HLA-C-restricted responses to identify novel targets for HIV-1 prophylactic and therapeutic strategies. IMPORTANCE Mass spectrometry (MS)-based approaches are increasingly being employed for large-scale identification of HLA-bound peptides derived from pathogens, but only very limited profiling of the HIV-1 immunopeptidome has been conducted to date. Notably, a growing body of evidence has recently begun to indicate a protective role for HLA-C in HIV-1 infection, which may suggest that despite the fact that levels of HLA-C expression on both uninfected and HIV-1-infected cells are lower than those of HLA-A/B, HLA-C still presents epitopes to CD8+ T cells effectively. To explore this, we analyzed HLA-C*12:02-restricted HIV-1 peptides presented on HIV-1-infected cells expressing only HLA-C*12:02 (a protective allele) using liquid chromatography-tandem MS (LC-MS/MS). We identified a number of novel HLA-C*12:02-bound HIV-1 peptides and showed that although the majority of them did not elicit T cell responses during natural infection in a Japanese cohort, they included three immunodominant epitopes, emphasizing the contribution of HLA-C to epitope presentation on HIV-infected cells., (Copyright © 2019 Chikata et al.)- Published
- 2019
- Full Text
- View/download PDF
24. Effective Suppression of HIV-1 Replication by Cytotoxic T Lymphocytes Specific for Pol Epitopes in Conserved Mosaic Vaccine Immunogens.
- Author
-
Zou C, Murakoshi H, Kuse N, Akahoshi T, Chikata T, Gatanaga H, Oka S, Hanke T, and Takiguchi M
- Subjects
- Amino Acid Sequence, Cell Line, Cross Reactions immunology, HIV Infections immunology, HIV Infections virology, HIV Seropositivity immunology, HIV Seropositivity virology, Humans, T-Lymphocytes, Cytotoxic virology, gag Gene Products, Human Immunodeficiency Virus immunology, AIDS Vaccines immunology, Conserved Sequence immunology, Epitopes, T-Lymphocyte immunology, Gene Products, pol immunology, HIV-1 immunology, T-Lymphocytes, Cytotoxic immunology, Virus Replication immunology
- Abstract
Cytotoxic T lymphocytes (CTLs) with strong abilities to suppress HIV-1 replication and recognize circulating HIV-1 could be key for both HIV-1 cure and prophylaxis. We recently designed conserved mosaic T-cell vaccine immunogens (tHIVconsvX) composed of 6 Gag and Pol regions. Since the tHIVconsvX vaccine targets conserved regions common to most global HIV-1 variants and employs a bivalent mosaic design, it is expected that it could be universal if the vaccine works. Although we recently demonstrated that CTLs specific for 5 Gag epitopes in the vaccine immunogens had strong ability to suppress HIV-1 replication in vitro and in vivo , it remains unknown whether the Pol region-specific CTLs are equally efficient. In this study, we investigated CTLs specific for Pol epitopes in the immunogens in treatment-naive Japanese patients infected with HIV-1 clade B. Overall, we mapped 20 reported and 5 novel Pol conserved epitopes in tHIVconsvX. Responses to 6 Pol epitopes were significantly associated with good clinical outcome, suggesting that CTLs specific for these 6 Pol epitopes had a strong ability to suppress HIV-1 replication in HIV-1-infected individuals. In vitro T-cell analyses further confirmed that the Pol-specific CTLs could effectively suppress HIV-1 replication. The present study thus demonstrated that the Pol regions of the vaccine contained protective epitopes. T-cell responses to the previous 5 Gag and present 6 Pol protective epitopes together also showed a strong correlation with better clinical outcome. These findings support the testing of the conserved mosaic vaccine in HIV-1 cure and prevention in humans. IMPORTANCE It is likely necessary for an effective AIDS vaccine to elicit CD8
+ T cells with the ability to recognize circulating HIV-1 and suppress its replication. We recently developed novel bivalent mosaic T-cell vaccine immunogens composed of conserved regions of the Gag and Pol proteins matched to at least 80% globally circulating HIV-1 isolates. Nevertheless, it remains to be proven if vaccination with these immunogens can elicit T cells with the ability to suppress HIV-1 replication. It is well known that Gag-specific T cells can suppress HIV-1 replication more effectively than T cells specific for epitopes in other proteins. We recently identified 5 protective Gag epitopes in the vaccine immunogens. In this study, we identified T cells specific for 6 Pol epitopes present in the immunogens with strong abilities to suppress HIV-1 in vivo and in vitro This study further encourages clinical testing of the conserved mosaic T-cell vaccine in HIV-1 prevention and cure., (Copyright © 2019 Zou et al.)- Published
- 2019
- Full Text
- View/download PDF
25. Broad Recognition of Circulating HIV-1 by HIV-1-Specific Cytotoxic T-Lymphocytes with Strong Ability to Suppress HIV-1 Replication.
- Author
-
Murakoshi H, Kuse N, Akahoshi T, Zhang Y, Chikata T, Borghan MA, Gatanaga H, Oka S, Sakai K, and Takiguchi M
- Subjects
- AIDS Vaccines, Cell Line, HIV Infections immunology, HIV-1 immunology, Humans, Japan, Mutation, Virus Replication, Epitopes, T-Lymphocyte immunology, HIV Infections virology, HIV-1 physiology, HLA-A Antigens metabolism, T-Lymphocytes, Cytotoxic metabolism
- Abstract
HIV-1-specific cytotoxic T-lymphocytes (CTLs) with strong abilities to suppress HIV-1 replication and recognize most circulating HIV-1 strains are candidates for effector T cells for cure treatment and prophylactic AIDS vaccine. Previous studies demonstrated that the existence of CTLs specific for 11 epitopes was significantly associated with good clinical outcomes in Japan, although CTLs specific for one of these epitopes select for escape mutations. However, it remains unknown whether the CTLs specific for the remaining 10 epitopes suppress HIV-1 replication in vitro and recognize circulating HIV-1. Here, we investigated the abilities of these CTLs to suppress HIV-1 replication and to recognize variants in circulating HIV-1. CTL clones specific for 10 epitopes had strong abilities to suppress HIV-1 replication in vitro The ex vivo and in vitro analyses of T-cell responses to variant epitope peptides showed that the T cells specific for 10 epitopes recognized mutant peptides which are detected in 84.1% to 98.8% of the circulating HIV-1 strains found in HIV-1-infected Japanese individuals. In addition, the T cells specific for 5 epitopes well recognized target cells infected with 7 mutant viruses that had been detected in >5% of tested individuals. Taken together, these results suggest that CTLs specific for the 10 epitopes effectively suppress HIV-1 replication and broadly recognize the circulating HIV-1 strains in the HIV-1-infected individuals. This study suggests the use of these T cells in clinical trials. IMPORTANCE In recent T-cell AIDS vaccine trials, the vaccines did not prevent HIV-1 infection, although HIV-1-specific T cells were induced in the vaccinated individuals, suggesting that the T cells have a weak ability to suppress HIV-1 replication and fail to recognize circulating HIV-1. We previously demonstrated that the T-cell responses to 10 epitopes were significantly associated with good clinical outcome. However, there is no direct evidence that these T cells have strong abilities to suppress HIV-1 replication and recognize circulating HIV-1. Here, we demonstrated that the T cells specific for the 10 epitopes had strong abilities to suppress HIV-1 replication in vitro Moreover, the T cells cross-recognized most of the circulating HIV-1 in HIV-1-infected individuals. This study suggests the use of T cells specific for these 10 epitopes in clinical trials of T-cell vaccines as a cure treatment., (Copyright © 2018 American Society for Microbiology.)
- Published
- 2018
- Full Text
- View/download PDF
26. Usefulness of Automated Latex Turbidimetric Rapid Plasma Reagin Test for Diagnosis and Evaluation of Treatment Response in Syphilis in Comparison with Manual Card Test: a Prospective Cohort Study.
- Author
-
Tsuboi M, Nishijima T, Aoki T, Teruya K, Kikuchi Y, Gatanaga H, and Oka S
- Subjects
- AIDS-Related Opportunistic Infections drug therapy, AIDS-Related Opportunistic Infections microbiology, Adult, Anti-Bacterial Agents administration & dosage, Antibodies, Bacterial blood, Automation, Laboratory, Cross-Sectional Studies, Female, Humans, Male, Middle Aged, Prospective Studies, Reagent Kits, Diagnostic standards, Reagins blood, Syphilis drug therapy, Syphilis microbiology, Time Factors, Treponema pallidum immunology, AIDS-Related Opportunistic Infections diagnosis, Drug Monitoring methods, Syphilis diagnosis, Syphilis Serodiagnosis methods, Syphilis Serodiagnosis standards, Treponema pallidum isolation & purification
- Abstract
The usefulness of an automated latex turbidimetric rapid plasma reagin (RPR) assay, compared to the conventional manual card test (serial 2-fold dilution method), for the diagnosis of syphilis and evaluation of treatment response remains unknown. We conducted (i) a cross-sectional study and (ii) a prospective cohort study to elucidate the correlation between automated and manual tests and whether a 4-fold decrement is a feasible criterion for successful treatment with the automated test, respectively, in HIV-infected patients, from October 2015 to November 2017. Study i included 518 patients. The results showed strong correlation between the two tests ( r = 0.931; P < 0.001). With a manual test titer of ≥1:8 plus a positive Treponema pallidum particle agglutination (TPPA) test as the reference standard for diagnosis, the optimal cutoff value for the automated test was 6.0 RPR units (area under the curve [AUC], 0.998), with positive predictive value (PPV) of 92.5% and negative predictive value (NPV) of 99.4%. Study ii enrolled 66 men with syphilis. Their RPR values were followed up until after 12 months of treatment. At 12 months, 77.3% and 78.8% of the patients achieved a 4-fold decrement in RPR titer by the automated and manual test, respectively. The optimal decrement rate in RPR titer by the automated test for a 4-fold decrement by manual card test was 76.54% (AUC, 0.96) (PPV, 96.1%; NPV, 80.0%). The automated RPR test is a good alternative to the manual test for the diagnosis of syphilis and evaluation of treatment response and is more rapid and can handle more specimens than the manual test without interpersonal variation in interpretation., (Copyright © 2018 American Society for Microbiology.)
- Published
- 2018
- Full Text
- View/download PDF
27. HLA Class I-Mediated HIV-1 Control in Vietnamese Infected with HIV-1 Subtype A/E.
- Author
-
Chikata T, Tran GV, Murakoshi H, Akahoshi T, Qi Y, Naranbhai V, Kuse N, Tamura Y, Koyanagi M, Sakai S, Nguyen DH, Nguyen DT, Nguyen HT, Nguyen TV, Oka S, Martin MP, Carrington M, Sakai K, Nguyen KV, and Takiguchi M
- Subjects
- Adult, Alleles, Asian People, CD4 Lymphocyte Count, Genotype, HIV Infections immunology, HIV Infections virology, HIV-1 pathogenicity, HLA-A Antigens genetics, HLA-A Antigens immunology, HLA-B7 Antigen genetics, HLA-B7 Antigen immunology, HLA-C Antigens genetics, HLA-C Antigens immunology, Haplotypes genetics, Haplotypes immunology, Host-Pathogen Interactions genetics, Host-Pathogen Interactions immunology, Humans, Mutation, Vietnam, Viral Load, Virus Replication, Genes, MHC Class I genetics, Genes, MHC Class I immunology, Genetic Fitness, HIV-1 genetics, HIV-1 immunology, pol Gene Products, Human Immunodeficiency Virus genetics, pol Gene Products, Human Immunodeficiency Virus immunology
- Abstract
HIV-1-specific cytotoxic T cells (CTLs) play an important role in the control of HIV-1 subtype B or C infection. However, the role of CTLs in HIV-1 subtype A/E infection still remains unclear. Here we investigated the association of HLA class I alleles with clinical outcomes in treatment-naive Vietnamese infected with subtype A/E virus. We found that HLA-C*12:02 was significantly associated with lower plasma viral loads (pVL) and higher CD4 counts and that the HLA-A*29:01-B*07:05-C*15:05 haplotype was significantly associated with higher pVL and lower CD4 counts than those for individuals without these respective genotypes. Nine Pol and three Nef mutations were associated with at least one HLA allele in the HLA-A*29:01-B*07:05-C*15:05 haplotype, with a strong negative correlation between the number of HLA-associated Pol mutations and CD4 count as well as a positive correlation with pVL for individuals with these HLA alleles. The results suggest that the accumulation of mutations selected by CTLs restricted by these HLA alleles affects HIV control. IMPORTANCE Most previous studies on HLA association with disease progression after HIV-1 infection have been performed on cohorts infected with HIV-1 subtypes B and C, whereas few such population-based studies have been reported for cohorts infected with the Asian subtype A/E virus. In this study, we analyzed the association of HLA class I alleles with clinical outcomes for 536 HIV-1 subtype A/E-infected Vietnamese individuals. We found that HLA-C*12:02 is protective, while the HLA haplotype HLA-A*29:01-B*07:05-C*15:05 is deleterious. The individuals with HIV-1 mutations associated with at least one of the HLA alleles in the deleterious HLA haplotype had higher plasma viral loads and lower CD4 counts than those of individuals without the mutations, suggesting that viral adaptation and escape from HLA-mediated immune control occurred. The present study identifies a protective allele and a deleterious haplotype for HIV-1 subtype A/E infection which are different from those identified for cohorts infected with HIV-1 subtypes B and C., (Copyright © 2018 American Society for Microbiology.)
- Published
- 2018
- Full Text
- View/download PDF
28. Accumulation of Pol Mutations Selected by HLA-B*52:01-C*12:02 Protective Haplotype-Restricted Cytotoxic T Lymphocytes Causes Low Plasma Viral Load Due to Low Viral Fitness of Mutant Viruses.
- Author
-
Murakoshi H, Koyanagi M, Chikata T, Rahman MA, Kuse N, Sakai K, Gatanaga H, Oka S, and Takiguchi M
- Subjects
- Alleles, Amino Acid Sequence, Epitopes chemistry, Epitopes immunology, Genotype, HIV Infections immunology, HIV Infections virology, HIV-1 physiology, Host-Pathogen Interactions, Humans, Virus Replication, Genetic Fitness, HLA-B Antigens immunology, Haplotypes, Mutation, T-Lymphocytes, Cytotoxic immunology, T-Lymphocytes, Cytotoxic metabolism, Viral Load, pol Gene Products, Human Immunodeficiency Virus genetics, pol Gene Products, Human Immunodeficiency Virus immunology
- Abstract
HLA-B*52:01-C*12:02, which is the most abundant haplotype in Japan, has a protective effect on disease progression in HIV-1-infected Japanese individuals, whereas HLA-B*57 and -B*27 protective alleles are very rare in Japan. A previous study on HLA-associated polymorphisms demonstrated that the number of HLA-B*52:01-associated mutations at four Pol positions was inversely correlated with plasma viral load (pVL) in HLA-B*52:01-negative individuals, suggesting that the transmission of HIV-1 with these mutations could modulate the pVL in the population. However, it remains unknown whether these mutations were selected by HLA-B*52:01-restricted CTLs and also reduced viral fitness. In this study, we identified two HLA-B*52:01-restricted and one HLA-C*12:02-restricted novel cytotoxic T-lymphocyte (CTL) epitopes in Pol. Analysis using CTLs specific for these three epitopes demonstrated that these CTLs failed to recognize mutant epitopes or more weakly recognized cells infected with mutant viruses than wild-type virus, supporting the idea that these mutations were selected by the HLA-B*52:01- or HLA-C*12:02-restricted T cells. We further showed that these mutations reduced viral fitness, although the effect of each mutation was weak. The present study demonstrated that the accumulation of these Pol mutations selected by HLA-B*52:01- or HLA-C*12:02-restricted CTLs impaired viral replication capacity and thus reduced the pVL. The fitness cost imposed by the mutations partially accounted for the effect of the HLA-B*52:01-C*12:02 haplotype on clinical outcome, together with the effect of HLA-B*52:01-restricted CTLs on viral replication, which had been previously demonstrated., Importance: Numerous population-based studies identified HLA-associated HIV-1 mutations to predict HIV-1 escape mutations from cytotoxic T lymphocytes (CTLs). However, the majority of these HLA-associated mutations have not been identified as CTL escape mutations. Our previous population-based study showed that five HLA-B*52:01-associated mutations at four Pol positions were inversely correlated with the plasma viral load in HLA-B*52:01-negative Japanese individuals. In the present study, we demonstrated that these mutations were indeed selected by CTLs specific for novel B*52:01- and C*12:02-restricted epitopes and that the accumulation of these mutations reduced the viral fitness in vitro This study elucidated the mechanism by which the accumulation of these CTL escape mutations contributed to the protective effect of the HLA-B*52:01-HLA-C*12:02 haplotype on disease progression in HIV-1-infected Japanese individuals., (Copyright © 2017 American Society for Microbiology.)
- Published
- 2017
- Full Text
- View/download PDF
29. Underestimated Amoebic Appendicitis among HIV-1-Infected Individuals in Japan.
- Author
-
Kobayashi T, Watanabe K, Yano H, Murata Y, Igari T, Nakada-Tsukui K, Yagita K, Nozaki T, Kaku M, Tsukada K, Gatanaga H, Kikuchi Y, and Oka S
- Subjects
- Adult, Aged, Antibodies, Protozoan blood, Appendix parasitology, Appendix pathology, Female, Histocytochemistry, Humans, Japan epidemiology, Male, Middle Aged, Polymerase Chain Reaction, Retrospective Studies, Seroepidemiologic Studies, Young Adult, Appendicitis epidemiology, Appendicitis etiology, Entamoeba histolytica isolation & purification, Entamoebiasis epidemiology, HIV Infections complications
- Abstract
Entamoeba histolytica is not a common causative agent of acute appendicitis. However, amoebic appendicitis can sometimes be severe and life threatening, mainly due to a lack of awareness. Also, its frequency, clinical features, and pathogenesis remain unclear. The study subjects were HIV-1-infected individuals who presented with acute appendicitis and later underwent appendectomy at our hospital between 1996 and 2014. Formalin-fixed paraffin-embedded preserved appendix specimens were reexamined by periodic acid-Schiff (PAS) staining and PCR to identify undiagnosed amoebic appendicitis. Appendectomies were performed in 57 patients with acute appendicitis. The seroprevalence of E. histolytica was 33% (14/43) from the available stored sera. Based on the medical records, only 3 cases were clinically diagnosed as amoebic appendicitis, including 2 diagnosed at the time of appendectomy and 1 case diagnosed by rereview of the appendix after the development of postoperative complications. Retrospective analyses using PAS staining and PCR identified 3 and 3 more cases, respectively. Thus, E. histolytica infection was confirmed in 9 cases (15.8%) in the present study. Apart from a significantly higher leukocyte count in E. histolytica-positive patients than in negative patients (median, 13,760 versus 10,385 cells/μl, respectively, P = 0.02), there were no other differences in the clinical features of the PCR-positive and -negative groups. In conclusion, E. histolytica infection was confirmed in 9 (15.8%) of the appendicitis cases. However, only 3, including one diagnosed after intestinal perforation, were diagnosed before the present analyses. These results strongly suggest there is frequently a failure to detect trophozoites in routine examination, resulting in an underestimation of the incidence of amoebic appendicitis., (Copyright © 2016 Kobayashi et al.)
- Published
- 2016
- Full Text
- View/download PDF
30. Different Effects of Nonnucleoside Reverse Transcriptase Inhibitor Resistance Mutations on Cytotoxic T Lymphocyte Recognition between HIV-1 Subtype B and Subtype A/E Infections.
- Author
-
Kuse N, Rahman MA, Murakoshi H, Tran GV, Chikata T, Koyanagi M, Nguyen KV, Gatanaga H, Oka S, and Takiguchi M
- Subjects
- Epitopes genetics, Epitopes immunology, Genotype, HIV Infections virology, HIV Reverse Transcriptase classification, Humans, Japan, Mutant Proteins genetics, Mutant Proteins immunology, Nucleosides therapeutic use, Reverse Transcriptase Inhibitors therapeutic use, Vietnam, Drug Resistance, Viral, HIV Reverse Transcriptase genetics, HIV Reverse Transcriptase immunology, Mutation, Missense, Nucleosides pharmacology, Reverse Transcriptase Inhibitors pharmacology, T-Lymphocytes, Cytotoxic immunology
- Abstract
Unlabelled: The effect of antiretroviral drug resistance mutations on cytotoxic T lymphocyte (CTL) recognition has been analyzed in HIV-1 subtype B infections, but it remains unclear in infections by other HIV-1 subtypes that are epidemic in countries where antiretroviral drugs are not effectively used. We investigated the effect of nonnucleoside reverse transcriptase (RT) inhibitor (NNRTI)-resistance mutations (Y181C, Y181I, and Y181V) on epitope recognition by CTLs specific for 3 different HIV-1 epitopes (HLA-A*02:01-restricted IV10, HLA-B*35:01-restricted NY9, and HLA-C*12:02-restricted KY9) in subtype B and subtype A/E infections and the accumulation of these mutations in treatment-naive Japanese and Vietnamese. These NNRTI-resistance mutations critically affected NY9-specific and KY9-specific T cell responses in the subtype B infections, whereas they showed a different effect on IV10-specific T cell responses among the subtype B-infected individuals. These mutations affected IV10-specific T cell responses but weakly affected NY9-specific T cell responses in the subtype A/E infections. The substitution at position 3 of NY9 epitope which was found in the subtype A/E virus differently influenced the peptide binding to HLA-B*35:01, suggesting that the differences in peptide binding may result in the differences in T cell recognition between the subtype B virus and A/E virus infections. The Y181C mutation was found to be accumulating in treatment-naive Vietnamese infected with the subtype A/E virus. The present study demonstrated different effects of NNRTI-resistance RT181 mutations on CTL responses between the 2 subtype infections. The Y181C mutation may influence HIV-1 control by the CTLs in Vietnam, since this mutation has been accumulating in treatment-naive Vietnamese., Importance: Antiretroviral therapy leads to the emergence of drug-resistant HIV-1, resulting in virological and clinical failures. Though HIV-1-specific CTLs play a critical role in HIV-1 infection, some of drug resistance mutations located in CTL epitopes are known to affect HIV-1-specific CTL responses. Nonnucleoside reverse transcriptase inhibitor (NNRTI)-resistance RT181 mutations are frequently observed in patients treated with NNRTIs. Such drug resistance mutations may have an influence on immune control by HIV-1-specific CTLs, especially in countries where antiretroviral drugs are not effectively used. We here investigated the effect of three NNRTI-resistance RT181 mutations on immune responses by HIV-1-specific CTLs and the recent accumulation of these mutations in treatment-naive Vietnamese infected with HIV-1 subtype A/E virus. RT181 mutations affected CTL recognition in both subtype A/E and B infections, while the RT Y181C mutation has been accumulating in treatment-naive Vietnamese. The results suggest that the Y181C mutation may influence HIV-1 control by CTLs in Vietnam., (Copyright © 2015, American Society for Microbiology. All Rights Reserved.)
- Published
- 2015
- Full Text
- View/download PDF
31. Clinical Control of HIV-1 by Cytotoxic T Cells Specific for Multiple Conserved Epitopes.
- Author
-
Murakoshi H, Akahoshi T, Koyanagi M, Chikata T, Naruto T, Maruyama R, Tamura Y, Ishizuka N, Gatanaga H, Oka S, and Takiguchi M
- Subjects
- AIDS Vaccines genetics, AIDS Vaccines immunology, Asian People genetics, CD4 Lymphocyte Count, Conserved Sequence, Cross Reactions, Epitopes, T-Lymphocyte genetics, HIV Antigens genetics, HIV Infections genetics, HIV-1 genetics, HLA-B Antigens genetics, HLA-B Antigens immunology, HLA-B27 Antigen genetics, HLA-B27 Antigen immunology, Host-Pathogen Interactions genetics, Host-Pathogen Interactions immunology, Humans, Mutagenesis, Site-Directed, Viral Load, gag Gene Products, Human Immunodeficiency Virus genetics, gag Gene Products, Human Immunodeficiency Virus immunology, nef Gene Products, Human Immunodeficiency Virus genetics, nef Gene Products, Human Immunodeficiency Virus immunology, pol Gene Products, Human Immunodeficiency Virus genetics, pol Gene Products, Human Immunodeficiency Virus immunology, Epitopes, T-Lymphocyte immunology, HIV Infections immunology, HIV Infections virology, HIV-1 immunology, T-Lymphocytes, Cytotoxic immunology, T-Lymphocytes, Cytotoxic virology
- Abstract
Unlabelled: Identification and characterization of CD8(+) T cells effectively controlling HIV-1 variants are necessary for the development of AIDS vaccines and for studies of AIDS pathogenesis, although such CD8(+) T cells have been only partially identified. In this study, we sought to identify CD8(+) T cells controlling HIV-1 variants in 401 Japanese individuals chronically infected with HIV-1 subtype B, in which protective alleles HLA-B*57 and HLA-B*27 are very rare, by using comprehensive and exhaustive methods. We identified 13 epitope-specific CD8(+) T cells controlling HIV-1 in Japanese individuals, though 9 of these epitopes were not previously reported. The breadths of the T cell responses to the 13 epitopes were inversely associated with plasma viral load (P = 2.2 × 10(-11)) and positively associated with CD4 count (P = 1.2 × 10(-11)), indicating strong synergistic effects of these T cells on HIV-1 control in vivo. Nine of these epitopes were conserved among HIV-1 subtype B-infected individuals, whereas three out of four nonconserved epitopes were cross-recognized by the specific T cells. These findings indicate that these 12 epitopes are strong candidates for antigens for an AIDS vaccine. The present study highlighted a strategy to identify CD8(+) T cells controlling HIV-1 and demonstrated effective control of HIV-1 by those specific for 12 conserved or cross-reactive epitopes., Importance: HLA-B*27-restricted and HLA-B*57-restricted cytotoxic T lymphocytes (CTLs) play a key role in controlling HIV-1 in Caucasians and Africans, whereas it is unclear which CTLs control HIV-1 in Asian countries, where HLA-B*57 and HLA-B*27 are very rare. A recent study showed that HLA-B*67:01 and HLA-B*52:01-C*12:02 haplotypes were protective alleles in Japanese individuals, but it is unknown whether CTLs restricted by these alleles control HIV-1. In this study, we identified 13 CTLs controlling HIV-1 in Japan by using comprehensive and exhaustive methods. They included 5 HLA-B*52:01-restricted and 3 HLA-B*67:01-restricted CTLs, suggesting that these CTLs play a predominant role in HIV-1 control. The 13 CTLs showed synergistic effects on HIV-1 control. Twelve out of these 13 epitopes were recognized as conserved or cross-recognized ones. These findings strongly suggest that these 12 epitopes are candidates for antigens for AIDS vaccines., (Copyright © 2015, American Society for Microbiology. All Rights Reserved.)
- Published
- 2015
- Full Text
- View/download PDF
32. Host-specific adaptation of HIV-1 subtype B in the Japanese population.
- Author
-
Chikata T, Carlson JM, Tamura Y, Borghan MA, Naruto T, Hashimoto M, Murakoshi H, Le AQ, Mallal S, John M, Gatanaga H, Oka S, Brumme ZL, and Takiguchi M
- Subjects
- Adult, Asian People, Genotype, HIV Infections immunology, HIV-1 immunology, HIV-1 isolation & purification, Histocompatibility Antigens Class I genetics, Histocompatibility Antigens Class I immunology, Humans, Immune Evasion, Japan epidemiology, Molecular Sequence Data, Mutation, Missense, Sequence Analysis, DNA, gag Gene Products, Human Immunodeficiency Virus genetics, nef Gene Products, Human Immunodeficiency Virus genetics, pol Gene Products, Human Immunodeficiency Virus genetics, Adaptation, Biological, HIV Infections virology, HIV-1 genetics
- Abstract
Unlabelled: The extent to which HIV-1 clade B strains exhibit population-specific adaptations to host HLA alleles remains incompletely known, in part due to incomplete characterization of HLA-associated HIV-1 polymorphisms (HLA-APs) in different global populations. Moreover, it remains unknown to what extent the same HLA alleles may drive significantly different escape pathways across populations. As the Japanese population exhibits distinctive HLA class I allele distributions, comparative analysis of HLA-APs between HIV-1 clade B-infected Japanese and non-Asian cohorts could shed light on these questions. However, HLA-APs remain incompletely mapped in Japan. In a cohort of 430 treatment-naive Japanese with chronic HIV-1 clade B infection, we identified 284 HLA-APs in Gag, Pol, and Nef using phylogenetically corrected methods. The number of HLA-associated substitutions in Pol, notably those restricted by HLA-B*52:01, was weakly inversely correlated with the plasma viral load (pVL), suggesting that the transmission and persistence of B*52:01-driven Pol mutations could modulate the pVL. Differential selection of HLA-APs between HLA subtype members, including those differing only with respect to substitutions outside the peptide-binding groove, was observed, meriting further investigation as to their mechanisms of selection. Notably, two-thirds of HLA-APs identified in Japan had not been reported in previous studies of predominantly Caucasian cohorts and were attributable to HLA alleles unique to, or enriched in, Japan. We also identified 71 cases where the same HLA allele drove significantly different escape pathways in Japan versus predominantly Caucasian cohorts. Our results underscore the distinct global evolution of HIV-1 clade B as a result of host population-specific cellular immune pressures., Importance: Cytotoxic T lymphocyte (CTL) escape mutations in HIV-1 are broadly predictable based on the HLA class I alleles expressed by the host. Because HLA allele distributions differ among worldwide populations, the pattern and diversity of HLA-associated escape mutations are likely to be somewhat distinct to each race and region. HLA-associated polymorphisms (HLA-APs) in HIV-1 have previously been identified at the population level in European, North American, Australian, and African cohorts; however, large-scale analyses of HIV-1 clade B-specific HLA-APs in Asians are lacking. Differential intraclade HIV-1 adaptation to global populations can be investigated via comparative analyses of HLA-associated polymorphisms across ethnic groups, but such studies are rare. Here, we identify HLA-APs in a large Japanese HIV-1 clade B cohort using phylogenetically informed methods and observe that the majority of them had not been previously characterized in predominantly Caucasian populations. The results highlight HIV's unique adaptation to cellular immune pressures imposed by different global populations.
- Published
- 2014
- Full Text
- View/download PDF
33. Evaluation of Combinations of 4'-Ethynyl-2-Fluoro-2'-Deoxyadenosine with Clinically Used Antiretroviral Drugs.
- Author
-
Hachiya A, Reeve AB, Marchand B, Michailidis E, Ong YT, Kirby KA, Leslie MD, Oka S, Kodama EN, Rohan LC, Mitsuya H, Parniak MA, and Sarafianos SG
- Abstract
Drug combination studies of 4'-ethynyl-2-fluoro-2'-deoxyadenosine (EFdA) with FDA-approved drugs were evaluated by two different methods, MacSynergy II and CalcuSyn. Most of the combinations, including the combination of the two adenosine analogs EFdA and tenofovir, were essentially additive, without substantial antagonism or synergism. The combination of EFdA and rilpivirine showed apparent synergism. These studies provide information that may be useful for the design of EFdA combination regimens for initial and salvage therapy assessment., (Copyright © 2013, American Society for Microbiology. All Rights Reserved.)
- Published
- 2013
- Full Text
- View/download PDF
34. Distinct HIV-1 escape patterns selected by cytotoxic T cells with identical epitope specificity.
- Author
-
Yagita Y, Kuse N, Kuroki K, Gatanaga H, Carlson JM, Chikata T, Brumme ZL, Murakoshi H, Akahoshi T, Pfeifer N, Mallal S, John M, Ose T, Matsubara H, Kanda R, Fukunaga Y, Honda K, Kawashima Y, Ariumi Y, Oka S, Maenaka K, and Takiguchi M
- Subjects
- Asian People, Epitopes, T-Lymphocyte genetics, HIV Infections immunology, HIV Infections virology, HIV Reverse Transcriptase genetics, HIV Reverse Transcriptase metabolism, HIV-1 genetics, HLA-B51 Antigen immunology, HLA-B51 Antigen metabolism, HLA-B52 Antigen immunology, HLA-B52 Antigen metabolism, Humans, Mutant Proteins genetics, Mutant Proteins metabolism, Mutation, Missense, Protein Binding, White People, Epitopes, T-Lymphocyte immunology, HIV-1 immunology, HIV-1 pathogenicity, Immune Evasion, Selection, Genetic, T-Lymphocytes, Cytotoxic immunology, T-Lymphocytes, Cytotoxic virology
- Abstract
Pol283-8-specific, HLA-B*51:01-restricted, cytotoxic T cells (CTLs) play a critical role in the long-term control of HIV-1 infection. However, these CTLs select for the reverse transcriptase (RT) I135X escape mutation, which may be accumulating in circulating HIV-1 sequences. We investigated the selection of the I135X mutation by CTLs specific for the same epitope but restricted by HLA-B*52:01. We found that Pol283-8-specific, HLA-B*52:01-restricted CTLs were elicited predominantly in chronically HIV-1-infected individuals. These CTLs had a strong ability to suppress the replication of wild-type HIV-1, though this ability was weaker than that of HLA-B*51:01-restricted CTLs. The crystal structure of the HLA-B*52:01-Pol283-8 peptide complex provided clear evidence that HLA-B*52:01 presents the peptide similarly to HLA-B*51:01, ensuring the cross-presentation of this epitope by both alleles. Population level analyses revealed a strong association of HLA-B*51:01 with the I135T mutant and a relatively weaker association of HLA-B*52:01 with several I135X mutants in both Japanese and predominantly Caucasian cohorts. An in vitro viral suppression assay revealed that the HLA-B*52:01-restricted CTLs failed to suppress the replication of the I135X mutant viruses, indicating the selection of these mutants by the CTLs. These results suggest that the different pattern of I135X mutant selection may have resulted from the difference between these two CTLs in the ability to suppress HIV-1 replication.
- Published
- 2013
- Full Text
- View/download PDF
35. Differential clade-specific HLA-B*3501 association with HIV-1 disease outcome is linked to immunogenicity of a single Gag epitope.
- Author
-
Matthews PC, Koyanagi M, Kløverpris HN, Harndahl M, Stryhn A, Akahoshi T, Gatanaga H, Oka S, Juarez Molina C, Valenzuela Ponce H, Avila Rios S, Cole D, Carlson J, Payne RP, Ogwu A, Bere A, Ndung'u T, Gounder K, Chen F, Riddell L, Luzzi G, Shapiro R, Brander C, Walker B, Sewell AK, Reyes Teran G, Heckerman D, Hunter E, Buus S, Takiguchi M, and Goulder PJ
- Subjects
- Africa, Southern, Disease Progression, Enzyme-Linked Immunospot Assay, Epitopes, T-Lymphocyte immunology, Flow Cytometry, Gene Products, gag immunology, HLA-B35 Antigen classification, HLA-B35 Antigen immunology, Humans, Japan, Mexico, Phylogeny, United Kingdom, Viral Load, CD8-Positive T-Lymphocytes immunology, Epitopes, T-Lymphocyte genetics, Gene Products, gag genetics, HIV Infections genetics, HIV Infections immunology, HIV-1, HLA-B35 Antigen genetics
- Abstract
The strongest genetic influence on immune control in HIV-1 infection is the HLA class I genotype. Rapid disease progression in B-clade infection has been linked to HLA-B*35 expression, in particular to the less common HLA-B*3502 and HLA-B*3503 subtypes but also to the most prevalent subtype, HLA-B*3501. In these studies we first demonstrated that whereas HLA-B*3501 is associated with a high viral set point in two further B-clade-infected cohorts, in Japan and Mexico, this association does not hold in two large C-clade-infected African cohorts. We tested the hypothesis that clade-specific differences in HLA associations with disease outcomes may be related to distinct targeting of critical CD8(+) T-cell epitopes. We observed that only one epitope was significantly targeted differentially, namely, the Gag-specific epitope NPPIPVGDIY (NY10, Gag positions 253 to 262) (P = 2 × 10(-5)). In common with two other HLA-B*3501-restricted epitopes, in Gag and Nef, that were not targeted differentially, a response toward NY10 was associated with a significantly lower viral set point. Nonimmunogenicity of NY10 in B-clade-infected subjects derives from the Gag-D260E polymorphism present in ∼90% of B-clade sequences, which critically reduces recognition of the Gag NY10 epitope. These data suggest that in spite of any inherent HLA-linked T-cell receptor repertoire differences that may exist, maximizing the breadth of the Gag-specific CD8(+) T-cell response, by the addition of even a single epitope, may be of overriding importance in achieving immune control of HIV infection. This distinction is of direct relevance to development of vaccines designed to optimize the anti-HIV CD8(+) T-cell response in all individuals, irrespective of HLA type.
- Published
- 2012
- Full Text
- View/download PDF
36. HLA class I-mediated control of HIV-1 in the Japanese population, in which the protective HLA-B*57 and HLA-B*27 alleles are absent.
- Author
-
Naruto T, Gatanaga H, Nelson G, Sakai K, Carrington M, Oka S, and Takiguchi M
- Subjects
- Alleles, Black People, CD4-Positive T-Lymphocytes chemistry, Cohort Studies, Disease Progression, Epitopes chemistry, Ethnicity, HLA Antigens genetics, Heterozygote, Homozygote, Humans, Japan, Phenotype, Viral Load, White People, HIV Infections immunology, HIV Infections prevention & control, HLA Antigens chemistry, HLA-B Antigens chemistry, HLA-B Antigens genetics, HLA-B27 Antigen chemistry, HLA-B27 Antigen genetics
- Abstract
We investigated the effect of HLA class I alleles on clinical parameters for HIV-1 disease progression in the Japanese population, where two strongly protective alleles, HLA-B*57 and HLA-B*27, are virtually nonexistent. HLA-B alleles showed a dominant role, primarily through HLA-B*67:01 and the HLA-B*52:01-C*12:02 haplotype. Neither a rare-allele nor a heterozygote advantage was found, suggesting that the effect of HLA alleles in the Japanese population is either different from those observed in Africans and Caucasians or undetectable due to limited power.
- Published
- 2012
- Full Text
- View/download PDF
37. Selection and accumulation of an HIV-1 escape mutant by three types of HIV-1-specific cytotoxic T lymphocytes recognizing wild-type and/or escape mutant epitopes.
- Author
-
Akahoshi T, Chikata T, Tamura Y, Gatanaga H, Oka S, and Takiguchi M
- Subjects
- Epitopes, T-Lymphocyte genetics, HIV Infections virology, HIV-1 physiology, Humans, T-Lymphocytes, Cytotoxic virology, Virus Replication, gag Gene Products, Human Immunodeficiency Virus genetics, gag Gene Products, Human Immunodeficiency Virus immunology, Epitopes, T-Lymphocyte immunology, HIV Infections immunology, HIV-1 genetics, HIV-1 immunology, HLA-A24 Antigen immunology, Mutation, T-Lymphocytes, Cytotoxic immunology
- Abstract
It is known that cytotoxic T lymphocytes (CTLs) recognizing HIV-1 escape mutants are elicited in HIV-1-infected individuals, but their role in the control of HIV-1 replication remains unclear. We investigated the antiviral ability of CTLs recognizing the HLA-A*24:02-restricted Gag28 -36 (KYKLKHIVW) epitope and/or its escape mutant (KYRLKHIVW) elicited in the early and chronic phases of the infection. Wild-type (WT)-epitope-specific CTLs, as well as cross-reactive CTLs recognizing both WT and K30R (3R) epitopes, which were predominantly elicited at early and/or chronic phases in HLA-A*24:02(+) individuals infected with the WT virus, suppressed the replication of the WT virus but failed to suppress that of the 3R virus, indicating that the 3R virus was selected by these 2 types of CTLs. On the other hand, cross-reactive and 3R-specific CTLs, which were elicited in those infected with the 3R virus, did not suppress the replication of either WT or 3R virus, indicating that these CTLs did not contribute to the control of 3R virus replication. High accumulation of the 3R mutation was found in a Japanese population recently recruited. The selection and accumulation of this 3R mutation resulted from the antiviral ability of these Gag28-specific CTLs and high prevalence of HLA-A*24:02 in a Japanese population. The present study highlighted the mechanisms for the roles of cross-reactive and mutant-epitope-specific CTLs, as well as high accumulation of escape mutants, in an HIV-1-infected population.
- Published
- 2012
- Full Text
- View/download PDF
38. Long-term control of HIV-1 in hemophiliacs carrying slow-progressing allele HLA-B*5101.
- Author
-
Kawashima Y, Kuse N, Gatanaga H, Naruto T, Fujiwara M, Dohki S, Akahoshi T, Maenaka K, Goulder P, Oka S, and Takiguchi M
- Subjects
- Alleles, Asian People genetics, CD8-Positive T-Lymphocytes immunology, CD8-Positive T-Lymphocytes virology, Disease Progression, Epitopes, HIV Infections complications, HIV Infections physiopathology, HIV Long-Term Survivors, HIV-1 physiology, Hemophilia A immunology, Hemophilia A virology, Humans, Kaplan-Meier Estimate, Models, Molecular, Mutation, Peptides genetics, Peptides immunology, Viral Load, Virus Replication, HIV Infections immunology, HIV-1 immunology, HLA-B Antigens genetics, HLA-B Antigens immunology, Hemophilia A complications, pol Gene Products, Human Immunodeficiency Virus immunology
- Abstract
HLA-B*51 alleles are reported to be associated with slow disease progression to AIDS, but the mechanism underlying this association is still unclear. In the present study, we analyzed the effect of HLA-B*5101 on clinical outcome for Japanese hemophiliacs who had been infected with HIV-1 before 1985 and had been recruited in 1998 for this study. HLA-B*5101(+) hemophiliacs exhibited significantly slow progression. The analysis of HLA-B*5101-restricted HIV-1-specific cytotoxic T-lymphocyte (CTL) responses to 4 HLA-B*-restricted epitopes in 10 antiretroviral-therapy (ART)-free HLA-B*5101(+) hemophiliacs showed that the frequency of Pol283-8-specific CD8(+) T cells was inversely correlated with the viral load, whereas the frequencies of CD8(+) T cells specific for 3 other epitopes were positively correlated with the viral load. The HLA-B*5101(+) hemophiliacs whose HIV-1 replication had been controlled for approximately 25 years had HIV-1 possessing the wild-type Pol283-8 sequence or the Pol283-8V mutant, which does not critically affect T-cell recognition, whereas other HLA-B*5101(+) hemophiliacs had HIV-1 with escape mutations in this epitope. The results suggest that the control of HIV-1 over approximately 25 years in HLA-B*5101-positive hemophiliacs is associated with a Pol283-8-specific CD8(+) T-cell response and that lack of control of HIV-1 is associated with the appearance of Pol283-8-specific escape mutants.
- Published
- 2010
- Full Text
- View/download PDF
39. Different in vivo effects of HIV-1 immunodominant epitope-specific cytotoxic T lymphocytes on selection of escape mutant viruses.
- Author
-
Koizumi H, Hashimoto M, Fujiwara M, Murakoshi H, Chikata T, Borghan MA, Hachiya A, Kawashima Y, Takata H, Ueno T, Oka S, and Takiguchi M
- Subjects
- HIV-1 physiology, HLA-A Antigens, HLA-A11 Antigen, Immunodominant Epitopes, Virus Replication, HIV-1 genetics, HIV-1 immunology, Immune Evasion genetics, Mutation immunology, Selection, Genetic immunology, T-Lymphocytes, Cytotoxic immunology
- Abstract
HIV-1 escape mutants are well known to be selected by immune pressure via HIV-1-specific cytotoxic T lymphocytes (CTLs) and neutralizing antibodies. The ability of the CTLs to suppress HIV-1 replication is assumed to be associated with the selection of escape mutants from the CTLs. Therefore, we first investigated the correlation between the ability of HLA-A*1101-restricted CTLs recognizing immunodominant epitopes in vitro and the selection of escape mutants. The result showed that there was no correlation between the ability of these CTLs to suppress HIV-1 replication in vitro and the appearance of escape mutants. The CTLs that had a strong ability to suppress HIV-1 replication in vitro but failed to select escape mutants expressed a higher level of PD-1 in vivo, whereas those that had a strong ability to suppress HIV-1 replication in vitro and selected escape mutants expressed a low level of PD-1. Ex vivo analysis of these CTLs revealed that the latter CTLs had a significantly stronger ability to recognize the epitope than the former ones. These results suggest that escape mutations are selected by HIV-1-specific CTLs that have a stronger ability to recognize HIV-1 in vivo but not in vitro.
- Published
- 2010
- Full Text
- View/download PDF
40. Combination of V106I and V179D polymorphic mutations in human immunodeficiency virus type 1 reverse transcriptase confers resistance to efavirenz and nevirapine but not etravirine.
- Author
-
Gatanaga H, Ode H, Hachiya A, Hayashida T, Sato H, and Oka S
- Subjects
- Alkynes, Amino Acid Substitution, Anti-HIV Agents chemistry, Benzoxazines chemistry, Cyclopropanes, Drug Resistance, Viral genetics, Genes, Viral, HIV Infections drug therapy, HIV Infections virology, HIV Reverse Transcriptase chemistry, HIV-1 isolation & purification, HIV-1 physiology, Humans, In Vitro Techniques, Models, Molecular, Mutation, Missense, Nevirapine chemistry, Nitriles, Pyridazines chemistry, Pyridazines pharmacology, Pyrimidines, Recombination, Genetic, Virus Replication drug effects, Virus Replication genetics, Anti-HIV Agents pharmacology, Benzoxazines pharmacology, HIV Reverse Transcriptase genetics, HIV-1 drug effects, HIV-1 genetics, Nevirapine pharmacology
- Abstract
Etravirine (ETV) is a second-generation nonnucleoside reverse transcriptase (RT) inhibitor (NNRTI) introduced recently for salvage antiretroviral treatment after the emergence of NNRTI-resistant human immunodeficiency virus type 1 (HIV-1). Following its introduction, two naturally occurring mutations in HIV-1 RT, V106I and V179D, were listed as ETV resistance-associated mutations. However, the effect of these mutations on the development of NNRTI resistance has not been analyzed yet. To select highly NNRTI-resistant HIV-1 in vitro, monoclonal HIV-1 strains harboring V106I and V179D (HIV-1(V106I) and HIV-1(V179D)) were propagated in the presence of increasing concentrations of efavirenz (EFV). Interestingly, V179D emerged in one of three selection experiments from HIV-1(V106I) and V106I emerged in two of three experiments from HIV-1(V179D). Analysis of recombinant HIV-1 clones showed that the combination of V106I and V179D conferred significant resistance to EFV and nevirapine (NVP) but not to ETV. Structural analysis indicated that ETV can overcome the repulsive interactions caused by the combination of V106I and V179D through fine-tuning of its binding module to RT facilitated by its plastic structure, whereas EFV and NVP cannot because of their rigid structures. Analysis of clinical isolates showed comparable drug susceptibilities, and the same combination of mutations was found in some database patients who experienced virologic NNRTI-based treatment failure. The combination of V106I and V179D is a newly identified NNRTI resistance pattern of mutations. The combination of polymorphic and minor resistance-associated mutations should be interpreted carefully.
- Published
- 2010
- Full Text
- View/download PDF
41. Strong ability of Nef-specific CD4+ cytotoxic T cells to suppress human immunodeficiency virus type 1 (HIV-1) replication in HIV-1-infected CD4+ T cells and macrophages.
- Author
-
Zheng N, Fujiwara M, Ueno T, Oka S, and Takiguchi M
- Subjects
- CD4-Positive T-Lymphocytes virology, Cells, Cultured, HIV Infections drug therapy, HIV Infections virology, HIV-1 immunology, Humans, Leukocytes, Mononuclear immunology, Leukocytes, Mononuclear virology, Macrophages immunology, T-Lymphocytes, Cytotoxic virology, nef Gene Products, Human Immunodeficiency Virus therapeutic use, CD4-Positive T-Lymphocytes immunology, Down-Regulation, HIV Infections immunology, HIV-1 physiology, Macrophages virology, T-Lymphocytes, Cytotoxic immunology, Virus Replication drug effects, nef Gene Products, Human Immunodeficiency Virus immunology
- Abstract
A restricted number of studies have shown that human immunodeficiency virus type 1 (HIV-1)-specific cytotoxic CD4+ T cells are present in HIV-1-infected individuals. However, the roles of this type of CD4+ T cell in the immune responses against an HIV-1 infection remain unclear. In this study, we identified novel Nef epitope-specific HLA-DRB1*0803-restricted cytotoxic CD4+ T cells. The CD4+ T-cell clones specific for Nef187-203 showed strong gamma interferon production after having been stimulated with autologous B-lymphoblastoid cells infected with recombinant vaccinia virus expressing Nef or pulsed with heat-inactivated virus particles, indicating the presentation of the epitope antigen through both exogenous and endogenous major histocompatibility complex class II processing pathways. Nef187-203-specific CD4+ T-cell clones exhibited strong cytotoxic activity against both HIV-1-infected macrophages and CD4+ T cells from an HLA-DRB1*0803+ donor. In addition, these Nef-specific cytotoxic CD4+ T-cell clones exhibited strong ability to suppress HIV-1 replication in both macrophages and CD4+ T cells in vitro. Nef187-203-specific cytotoxic CD4+ T cells were detected in cultures of peptide-stimulated peripheral blood mononuclear cells (PBMCs) and in ex vivo PBMCs from 40% and 20% of DRB1*0803+ donors, respectively. These results suggest that HIV-1-specific CD4+ T cells may directly control HIV-1 infection in vivo by suppressing virus replication in HIV-1 natural host cells.
- Published
- 2009
- Full Text
- View/download PDF
42. Amino acid mutation N348I in the connection subdomain of human immunodeficiency virus type 1 reverse transcriptase confers multiclass resistance to nucleoside and nonnucleoside reverse transcriptase inhibitors.
- Author
-
Hachiya A, Kodama EN, Sarafianos SG, Schuckmann MM, Sakagami Y, Matsuoka M, Takiguchi M, Gatanaga H, and Oka S
- Subjects
- Animals, Cell Line, HIV Infections virology, HIV-1 genetics, HIV-1 isolation & purification, Humans, Microbial Sensitivity Tests, Models, Molecular, Sequence Analysis, DNA, Virus Replication genetics, Amino Acid Substitution, Drug Resistance, Viral genetics, HIV Reverse Transcriptase genetics, HIV-1 drug effects, Nevirapine pharmacology, Reverse Transcriptase Inhibitors pharmacology
- Abstract
We identified clinical isolates with phenotypic resistance to nevirapine (NVP) in the absence of known nonnucleoside reverse transcriptase inhibitor (NNRTI) mutations. This resistance is caused by N348I, a mutation at the connection subdomain of human immunodeficiency virus type 1 (HIV-1) reverse transcriptase (RT). Virologic analysis showed that N348I conferred multiclass resistance to NNRTIs (NVP and delavirdine) and to nucleoside reverse transcriptase inhibitors (zidovudine [AZT] and didanosine [ddI]). N348I impaired HIV-1 replication in a cell-type-dependent manner. Acquisition of N348I was frequently observed in AZT- and/or ddI-containing therapy (12.5%; n = 48; P < 0.0001) and was accompanied with thymidine analogue-associated mutations, e.g., T215Y (n = 5/6) and the lamivudine resistance mutation M184V (n = 1/6) in a Japanese cohort. Molecular modeling analysis shows that residue 348 is proximal to the NNRTI-binding pocket and to a flexible hinge region at the base of the p66 thumb that may be affected by the N348I mutation. Our results further highlight the role of connection subdomain residues in drug resistance.
- Published
- 2008
- Full Text
- View/download PDF
43. Different abilities of escape mutant-specific cytotoxic T cells to suppress replication of escape mutant and wild-type human immunodeficiency virus type 1 in new hosts.
- Author
-
Fujiwara M, Tanuma J, Koizumi H, Kawashima Y, Honda K, Mastuoka-Aizawa S, Dohki S, Oka S, and Takiguchi M
- Subjects
- Amino Acid Substitution, Epitopes genetics, Epitopes immunology, HIV Infections transmission, HIV-1 genetics, HLA-A Antigens immunology, HLA-A24 Antigen, Humans, nef Gene Products, Human Immunodeficiency Virus genetics, nef Gene Products, Human Immunodeficiency Virus immunology, HIV Infections immunology, HIV Infections virology, HIV-1 immunology, Mutation, T-Lymphocytes, Cytotoxic immunology
- Abstract
There is much evidence that in human immunodeficiency virus type 1 (HIV-1)-infected individuals, strong cytotoxic T lymphocyte (CTL)-mediated immune pressure results in the selection of HIV-1 mutants that have escaped from wild-type-specific CTLs. If escape mutant-specific CTLs are not elicited in new hosts sharing donor HLA molecules, the transmission of these mutants results in the accumulation of escape mutants in the population. However, whether escape mutant-specific CTLs are definitively not elicited in new hosts sharing donor HLA molecules still remains unclear. A previous study showed that a Y-to-F substitution at the second position (2F) of the Nef138-10 epitope is significantly detected in HLA-A*2402(+) hemophilic donors. Presently, we confirmed that this 2F mutant was an escape mutant by demonstrating strong and weak abilities of Nef138-10-specific CTL clones to suppress replication of the wild-type and 2F mutant viruses, respectively. We demonstrated the existence of the 2F-specific CTLs in three new hosts who had been primarily infected with the 2F mutant. The 2F-specific CTL clones suppressed the replication of both wild-type and mutant viruses. However, the abilities of these clones to suppress replication of the 2F virus were much weaker than those of wild-type-specific and the 2F-specific ones to suppress replication of the wild-type virus. These findings indicate that the 2F mutant is conserved in HIV-1-infected donors having HLA-A*2402, because the 2F-specific CTLs failed to completely suppress the 2F mutant replication and effectively prevented viral reversion in new hosts carrying HLA-A*2402.
- Published
- 2008
- Full Text
- View/download PDF
44. Patterns of cytokine production in human immunodeficiency virus type 1 (HIV-1)-specific human CD8+ T cells after stimulation with HIV-1-infected CD4+ T cells.
- Author
-
Fujiwara M, Takata H, Oka S, Tomiyama H, and Takiguchi M
- Subjects
- Chemokine CCL4, Humans, Interferon-gamma analysis, Macrophage Inflammatory Proteins analysis, T-Lymphocyte Subsets immunology, T-Lymphocytes, Cytotoxic immunology, Tumor Necrosis Factor-alpha analysis, CD4-Positive T-Lymphocytes virology, Cytokines analysis, HIV-1 immunology, Lymphocyte Activation
- Abstract
Although human immunodeficiency virus type 1 (HIV-1)-specific CD8+ T cells can produce various cytokines that suppress HIV-1 replication or modulate anti-HIV-1 immunity, the extent to which HIV-1-specific CD8+ T cells produce cytokines when they recognize HIV-1-infected CD4+ T cells in vivo still remains unclear. We first analyzed the abilities of 10 cytotoxic T-lymphocyte (CTL) clones specific for three HIV-1 epitopes to produce gamma interferon, macrophage inflammatory protein 1beta, and tumor necrosis factor alpha after stimulation with epitope peptide-pulsed cells. These CTL clones produced these cytokines in various combinations within the same specificity and among the different specificities, suggesting a functional heterogeneity of HIV-1-specific effector CD8+ T cells in cytokine production. In contrast, the HIV-1-specific CTL clones for the most part produced a single cytokine, without heterogeneity of cytokine production among the clones, after stimulation with HIV-1-infected CD4+ T cells. The loss of heterogeneity in cytokine production may be explained by low surface expression of HLA class I-epitope peptide complexes. Freshly isolated HIV-1-specific CD8+ T cells with an effector/memory or memory phenotype produced much more of the cytokines than the same epitope-specific CTL clones when stimulated with HIV-1-infected CD4+ T cells. Cytokine production from HIV-1-specific memory/effector and memory CD8+ T cells might be a critical event in the eradication of HIV-1 in HIV-1-infected individuals.
- Published
- 2005
- Full Text
- View/download PDF
45. Isolation and molecular characterization of a nelfinavir (NFV)-resistant human immunodeficiency virus type 1 that exhibits NFV-dependent enhancement of replication.
- Author
-
Matsuoka-Aizawa S, Sato H, Hachiya A, Tsuchiya K, Takebe Y, Gatanaga H, Kimura S, and Oka S
- Subjects
- Blotting, Western, Genes, gag, HIV Envelope Protein gp41 metabolism, HIV Protease genetics, HIV-1 genetics, Humans, Male, Drug Resistance, Viral, HIV Protease Inhibitors pharmacology, HIV-1 drug effects, Nelfinavir pharmacology, Virus Replication drug effects
- Abstract
During the use of a phenotypic anti-human immunodeficiency virus type 1 (HIV-1) drug resistance assay in a large set of clinical virus isolates, we found a unique variant (CL-4) that exhibited a high level of nelfinavir (NFV) resistance and rather enhanced replication under subinhibitory concentrations of NFV (0.001 to 0.1 micro M). Comparison of gag-pol sequences of the CL-4 variant and its predecessor virus isolates showed a stepwise accumulation of a total of 19 amino acid substitutions in protease (PR) and Gag p17 during 32-month NFV-containing antiretroviral therapy, while other Gag regions including the cleavage sites of the p55 precursor remained highly conserved. To understand the relationship between the genetic and phenotypic changes in CL-4, we constructed chimeric viruses using pNL4-3, replacing the PR, p24PR, or p17PR gene segment of CL-4 or its predecessor. A series of tissue culture infections with the chimeras in the absence or presence of increasing concentrations of NFV demonstrated that only the p17PR segment of CL-4 could confer the NFV-dependent replication enhancement phenotype on NL4-3. Our data suggest a novel adaptation mechanism of HIV-1 to NFV, in which coevolution of Gag and PR genes generates a variant that replicates more efficiently in the cellular environment in the presence of NFV than without the drug.
- Published
- 2003
- Full Text
- View/download PDF
46. Augmentation of human immunodeficiency virus type 1 subtype E (CRF01_AE) multiple-drug resistance by insertion of a foreign 11-amino-acid fragment into the reverse transcriptase.
- Author
-
Sato H, Tomita Y, Ebisawa K, Hachiya A, Shibamura K, Shiino T, Yang R, Tatsumi M, Gushi K, Umeyama H, Oka S, Takebe Y, and Nagai Y
- Subjects
- Adult, Amino Acid Sequence, Anti-HIV Agents pharmacology, Base Sequence, Child, Drug Resistance, Microbial, Drug Resistance, Multiple, Female, Gene Products, pol genetics, HIV Reverse Transcriptase chemistry, HIV-1 chemistry, Humans, Male, Models, Molecular, Molecular Sequence Data, Phylogeny, Reverse Transcriptase Inhibitors pharmacology, Evolution, Molecular, HIV Infections virology, HIV Reverse Transcriptase genetics, HIV-1 drug effects, HIV-1 genetics, Mutagenesis, Site-Directed
- Abstract
A human immunodeficiency virus type 1 (HIV-1) subtype E (CRF01_AE) variant (99JP-NH3-II) possessing an in-frame 33-nucleotide insertion mutation in the beta3-beta4 loop coding region of the reverse transcriptase (RT) gene was isolated from a patient who had not responded to nucleoside analogue RT inhibitors. This virus exhibited an extremely high level of multiple nucleoside analog resistance (MNR). Neighbor-joining tree analysis of the pol sequences indicated that the 99JP-NH3-II variant had originated from the swarm of drug-sensitive predecessors in the patient. Population-based sequence analyses of 82 independently cloned RT segments from the patient suggested that the variants with the insertion, three or four 3'-azido-3'-deoxythymidine resistance mutations, and a T69I mutation in combination had strong selective advantages during chemotherapy. Consistently, in vitro mutagenesis of a drug-sensitive predecessor virus clone demonstrated that this mutation set functions cooperatively to confer a high level of MNR without deleterious effects on viral replication capability. Homology modeling of the parental RT and its MNR mutant showed that extension of the beta3-beta4 loop by an insertion caused reductions in the distances between the loop and the other subdomains, narrowing the template-primer binding cleft and deoxynucleoside triphosphate-binding pocket in a highly flexible manner. The origin of the insert is elusive, as every effort to find a homologue has been unsuccessful. Taken together, these data suggest that (i) HIV-1 tolerates in vivo insertions as long as 33 nucleotides into the highly conserved enzyme gene to survive multiple anti-HIV-1 inhibitors and (ii) the insertion mutation augments multiple-drug resistance, possibly by reducing the biochemical inaccuracy of substrate-enzyme interactions in the active center.
- Published
- 2001
- Full Text
- View/download PDF
47. Rapid and simple phenotypic assay for drug susceptibility of human immunodeficiency virus type 1 using CCR5-expressing HeLa/CD4(+) cell clone 1-10 (MAGIC-5).
- Author
-
Hachiya A, Aizawa-Matsuoka S, Tanaka M, Takahashi Y, Ida S, Gatanaga H, Hirabayashi Y, Kojima A, Tatsumi M, and Oka S
- Subjects
- Amino Acid Sequence, Clone Cells, Flow Cytometry, Genotype, HIV Infections virology, HIV-1 genetics, HeLa Cells, Humans, Indicators and Reagents, Microbial Sensitivity Tests, Molecular Sequence Data, Mutation genetics, Phenotype, Receptors, CXCR4 biosynthesis, Receptors, CXCR4 genetics, Reverse Transcriptase Polymerase Chain Reaction, Anti-HIV Agents pharmacology, CD4 Antigens genetics, HIV-1 drug effects, Receptors, CCR5 biosynthesis
- Abstract
We describe a rapid and simple novel phenotypic assay for drug susceptibility of human immunodeficiency virus type-1 (HIV-1) using a CCR5-expressing HeLa/CD4(+) cell clone 1-10 (MAGIC-5). MAGIC-5 cells produced large amounts of HIV-1 in culture supernatants, which enabled us to perform the phenotypic resistance assay. Determination of HIV-1 susceptibility to various protease inhibitors (PI) and nucleoside reverse transcriptase inhibitors was completed within 15 days in T-cell-tropic (X4) and macrophage-tropic (R5) viruses using fresh plasma samples containing at least 10(4) copies/ml. The nucleotide sequence of the envelope V3 region of HIV-1 in plasma was almost identical to that of the virus isolated by MAGIC-5 cells, suggesting a lack of selection bias in our assay. The assay variability was confined to within five-fold in all drugs examined. Accordingly, we used a 10-fold increase in the 50% inhibitory concentration as the cutoff value for viral resistance in the present assay. HIV-1 resistant to lamivudine, which was not detected by conventional genotypic assays, was isolated. In HIV-1 with PI-associated primary amino acid substitutions, our assay showed that drug resistance profiles correlated well with previously reported genotypic-assay data. Furthermore, our assay provided comprehensive results regarding PI resistance in the presence of multiple mutations. The novel assay successfully quantified the level of resistance of clinical HIV-1 isolates to a battery of anti-HIV drugs, indicating its clinical usefulness, particularly in patients who failed to respond to antiretroviral chemotherapy.
- Published
- 2001
- Full Text
- View/download PDF
48. Recombinant p51 as antigen in an immune complex transfer enzyme immunoassay of immunoglobulin G antibody to human immunodeficiency virus type 1.
- Author
-
Hashinaka K, Hashida S, Nishikata I, Adachi A, Oka S, and Ishikawa E
- Subjects
- Adult, Aged, Amino Acid Sequence, Antigen-Antibody Complex, Base Sequence, DNA Primers genetics, Enzyme-Linked Immunosorbent Assay, Female, HIV Reverse Transcriptase genetics, HIV Reverse Transcriptase immunology, HIV Seropositivity immunology, HIV-1 enzymology, Humans, Male, Middle Aged, Plasmids genetics, Recombinant Proteins genetics, Recombinant Proteins immunology, HIV Antibodies blood, HIV Antigens genetics, HIV-1 genetics, HIV-1 immunology, Immunoenzyme Techniques methods, Immunoglobulin G blood
- Abstract
An ultrasensitive enzyme immunoassay (immune complex transfer enzyme immunoassay) of antibody immunoglobulin G (IgG) to human immunodeficiency virus type 1 (HIV-1) has been developed using recombinant HIV-1 reverse transcriptase (rRT) as antigen. However, some disadvantages were noted in the use of rRT as antigen: rRT was produced only with low efficiency in widely used strains of Escherichia coli using a rather long DNA fragment (3,012 bp) of the whole HIV-1 pol gene, and it was impossible to produce fusion proteins of RT for simple purification, since rRT is a heterodimer of p66 and p51. In this study, recombinant HIV-1 p51 and p66 with Ser-Ser at the N termini (Ser-Ser-rp51 and Ser-Ser-rp66) were produced in E. coli as fusion proteins with maltose binding protein containing a factor Xa site between the two proteins and were purified after digestion with factor Xa. Ser-Ser-rp51 was produced in larger amounts and purified in higher yields with less polymerization than Ser-Ser-rp66. Polymerized Ser-Ser-rp66 tended to be precipitated on mercaptoacetylation for conjugation to beta-D-galactosidase (used as a label) and showed higher nonspecific and lower specific signals in an immune complex transfer enzyme immunoassay of antibody IgG to HIV-1 than Ser-Ser-rp51. The signals for serum samples of HIV-1-seropositive subjects by immune complex transfer enzyme immunoassay of antibody IgG to HIV-1 using Ser-Ser-rp51 as antigen (Y) were well correlated to those obtained using rRT as antigen (X) (log Y = 0.99 log X + 0.23; r = 0.99). Thus, the use of rp51 as antigen was advantageous over that of rp66 and rRT in an immune complex transfer enzyme immunoassay of antibody IgG to HIV-1.
- Published
- 2000
- Full Text
- View/download PDF
49. Earlier detection of human immunodeficiency virus type 1 p24 antigen and immunoglobulin G and M antibodies to p17 antigen in seroconversion serum panels by immune complex transfer enzyme immunoassays.
- Author
-
Hashida S, Ishikawa S, Hashinaka K, Nishikata I, Oka S, and Ishikawa E
- Subjects
- HIV Infections diagnosis, HIV Infections immunology, HIV Infections virology, HIV Seropositivity virology, HIV-1 genetics, HIV-1 immunology, HIV-1 isolation & purification, Humans, Immunoenzyme Techniques statistics & numerical data, Immunoglobulin G blood, Immunoglobulin M blood, RNA, Viral blood, RNA, Viral genetics, Reverse Transcriptase Polymerase Chain Reaction, Sensitivity and Specificity, Time Factors, gag Gene Products, Human Immunodeficiency Virus, Gene Products, gag immunology, HIV Antibodies blood, HIV Antigens immunology, HIV Core Protein p24 blood, HIV Seropositivity diagnosis, HIV Seropositivity immunology, Immunoenzyme Techniques methods, Viral Proteins
- Abstract
For earlier diagnosis of human immunodeficiency virus type 1 (HIV-1) infection, the sensitivities of immune complex transfer enzyme immunoassays for HIV-1 p24 antigen and antibody immunoglobulin G (IgG) to HIV-1 p17 antigen were improved approximately 25- and 90-fold, respectively, over those of the previous immunoassays by performing solid-phase immunoreactions with shaking and increasing the serum sample volumes, and immune complex transfer enzyme immunoassay of antibody IgM to p17 antigen was also performed in the same way as the improved immunoassay of antibody IgG to p17 antigen. By the improved immunoassays, p24 antigen and antibody IgG to p17 antigen were detected earlier in 32 and 53%, respectively, of the HIV-1 seroconversion serum panels tested than before the improvements, and p24 antigen was detected as early as or earlier than HIV-1 RNA by reverse transcriptase-PCR (RT-PCR) in all of the panels tested. In 4 panels out of 19 tested, antibody IgG to p17 antigen or both antibodies IgG and IgM to p17 antigen were detected earlier than p24 antigen and RNA, although the antibody levels declined slightly before their steep increases usually observed after p24 antigen and RNA. Thus, the window period in diagnosis of HIV-1 infection can be shortened by detection of p24 antigen with the improved immunoassay as much as by detection of RNA with RT-PCR and, in some cases, more by detection of antibodies IgG and IgM to p17 antigen with the improved immunoassays than by detections of p24 antigen with the improved immunoassay and RNA with RT-PCR.
- Published
- 2000
- Full Text
- View/download PDF
50. Polymorphism in the interleukin-4 promoter affects acquisition of human immunodeficiency virus type 1 syncytium-inducing phenotype.
- Author
-
Nakayama EE, Hoshino Y, Xin X, Liu H, Goto M, Watanabe N, Taguchi H, Hitani A, Kawana-Tachikawa A, Fukushima M, Yamada K, Sugiura W, Oka SI, Ajisawa A, Sato H, Takebe Y, Nakamura T, Nagai Y, Iwamoto A, and Shioda T
- Subjects
- Alleles, Base Sequence, Chemokine CCL5 genetics, Disease Progression, Female, Gene Frequency genetics, Genotype, HIV Infections blood, HIV Infections immunology, HIV Infections virology, HIV-1 immunology, HIV-1 pathogenicity, Haplotypes genetics, Hemophilia A, Heterosexuality, Humans, Immunoglobulin E blood, Interleukin-10 genetics, Japan, Male, Molecular Sequence Data, Phenotype, Polymorphism, Restriction Fragment Length, Giant Cells pathology, HIV Infections pathology, HIV-1 physiology, Interleukin-4 genetics, Polymorphism, Genetic genetics, Promoter Regions, Genetic genetics
- Abstract
The emergence of syncytium-inducing (SI) variants of human immunodeficiency virus type 1 (HIV-1) in infected individuals is an indicator of poor prognosis and is often correlated with faster CD4(+) cell depletion and rapid disease progression. Interleukin-4 (IL-4) is a pleiotropic cytokine with various immune-modulating functions including induction of immunoglobulin E (IgE) production in B cells, down-regulation of CCR5 (a coreceptor for HIV-1 non-SI [NSI] strains), and up-regulation of CXCR4 (a coreceptor for HIV-1 SI variants). Here we show that homozygosity of a polymorphism in the IL-4 promoter region, IL-4 -589T, is correlated with increased rates of SI variant acquisition in HIV-1-infected individuals in Japan. This mutation was also shown to be associated with elevated serum IgE levels in HIV-1-infected individuals, especially in those at advanced stages of disease. In contrast, neither a triallele polymorphism in IL-10, another Th2 cytokine, nor a biallele polymorphism in the RANTES promoter affected acquisition of the SI phenotype. This finding suggested that IL-4-589T increases IL-4 production in the human body and thus accelerates the phenotypic switch of HIV-1 from NSI to SI and possibly disease progression of AIDS.
- Published
- 2000
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.